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CHAPTER 1: INTRODUCTION
‘It must be remembered that there is nothing more difficult to plan, more doubtful of
success, nor more dangerous to manage than the creation of a new system. For the initiator has the
enmity of all who would profit by the preservation of the old institutions and merely lukewarm
defenders of those who would gain by the new ones.’
Niccolo Machiavelli (1469 - 1527)
Healthcare within the past several decades have seen an impetus towards precision
medicine leading to “dramatic changes in how health care is delivered.”

1

This growth has

generated an expansive industry that produces genome- and molecular-based laboratory tests,
reagents and protocols required to detect and treat illnesses. In the laboratory, these new diagnostic
methods are referred to as “Laboratory Developed Tests” or LDT.

2

LDT are defined as a sub-set

of in vitro diagnostics (IVDs) that are “intended for clinical use and designed, manufactured and
used within a single laboratory”.2 Historically, tests were developed by medical laboratories on a
small scale, but as the interest in molecular testing expanded, large diagnostic manufacturers also
began to develop and mass market LDT.2 (3) Governmental public safety agencies became
interested in the marketing claims stated by these manufactures and the accompanying medical
outcomes.4
In 2004, poorly validated research alerted the FDA to a laboratory industry that lacks
regulatory oversight and structure for design, development and testing of LDT. 56 Historically,
laboratories were under enforcement discretion by the Food and Drug administration and have
adverted the approval process as required for laboratory test kit manufactures under the medical
device act F, D & C and 21 CFR 820.4 The test registration and regulatory approval process is
difficult to manage and according to the Centers for Medicare & Medicaid Services (CMS), there
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are approximately 254,000 laboratory entities in the U.S. with 335,700 medical technologists and
technicians. In addition, the expansion of genetic testing also contributes to the complexity and
introduces a significant amount of test variation to field of LDT. 11, 61
In addition, a significant gap exists between the Clinical Laboratory Improvement Act (CLIA)
established for laboratory accreditation and FDA regulations.
To address this issue, the FDA proposed a rigorous approval process to reduce or eliminate
the potential for error in healthcare like that required for manufacturers of medical device in a draft
guidance entitled Framework for Regulatory Oversight of Laboratory Developed Tests.3 In this
draft guidance, the FDA presents the agency approach for LDT oversight as a public health risk”.
2, 3

In addition, the FDA proposes a process for risk classification, time frames for LDT

registration, a formalized design control structure and a phased implementation plan for a Quality
System Regulation (QSR) for laboratories that register LDT for high risk or moderate risk
classifications.2 Laboratories developing rare LDTs are exempt from the requirements described
in the proposal because as described, the outcome of an incorrect result or incorrect interpretation
is unlikely to affect morbidity, mortality or the safety of patients. 3
This QSR management structure is presented from a medical device perspective and
encompasses a structure consisting of management responsibilities, procedures, processes, and
resources to ensure patient safety. Laboratories disputed the FDA oversight and QSR structure
comprised of medical device requirements and challenged the applicability to diagnostic testing.
42

Many laboratories may lack the resources or regulatory understanding to develop a quality

system program that meets FDA specifications.44
The draft guidance resulted in significant resistance from the laboratory community and
following a period of public comment, the Agency announced, in a Discussion Paper dated January

3
13, 2017, that they were considering possible alternatives to the original framework.

6,7

The FDA

continues the proposition for regulatory requirements from the 2014 draft guidance and
emphasizes the adoption of a (QSR) for the development of LDT that include design controls,
acceptance criteria and corrective and preventive action procedures as referred to in the 2017
Discussion Paper. 6, Moreover, the laboratories continue to struggle to understand the implications
of this additional regulatory oversight, and their responsibility to comply in the event the draft
guidance becomes policy.
Motivation for this Research
The motivation of this study is to understand regulatory requirements, laboratory
constraints and necessary factors to design, develop and implement a regulatory quality
management system for laboratories that perform high risk and moderate risk LDT. In the absence
of a required laboratory accreditation quality management system standard, I will explore
requirements as mandated for the medical device industry and understand how these principles
especially product development methodology of design control may align and be applicable to
laboratory testing. 14
Through this study I will investigate, develop, design and address management practices
that will best support unique product variation, accuracy of results particularly important for
addressing the patient safety concerns of the FDA and speed of processing within a high -volume
routine automated laboratory. The framework will incorporate process standardization to support
manufacturing requirements of product, people and service. I will explore the applicability of the
agile product development technique to a laboratory environment that will assist laboratories
comply with all pertinent regulations and expedite test development. 47
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The problem is as follows: If the FDA mandates an adoption of a Quality System Regulation for
the process of Laboratory Developed Tests, how will laboratories design, adopt and implement a
quality management system that commit to this requirement.
Research Goals
The inspiration to conduct this research is expressed through my lifelong commitment and
contribution to positively affect healthcare. My career began in a recovery facility where I cared
for the sick, elderly and disabled and it was there that I developed a concern for the welfare of
people who were unable to care for themselves. It was through this experience that I discovered
my passion for patient safety and consequently has persisted as the focal point of my work. I spent
many years in laboratories and later as a consultant that assisted leadership achieve increase levels
of quality through waste elimination and process standardization. This research study to explore
the perceived apprehension associated with laboratory testing, the associated literature review and
the call for action by governmental agencies opened my eyes to a reality of an industry that lacks
regulatory controls and oversight for diagnostic tests, a service, that clinicians and patients depend
for treatment decisions.
From a practical perspective, the proposed FDA recommendations, if implemented
effectively, could transform healthcare on a global level and set the world standard for global
laboratory quality.
The scholarly goals of the proposed changes as recommended by the FDA can be described
as an impetus to change within a historically stable regulatory laboratory environment. These
recommendations by the FDA may guide the current state of laboratories into futuristic change.

5
Scope of this Research
The scope of this research is limited to laboratories actively developing in house high risk
and moderate risk LDTs within a system that has yet to understand, define and implement
regulatory processes that align with pertinent regulations for patient safety as proposed by the
FDA. The development of rare LDTs is out of the scope of this research due to the exemption
status described in the 2014 draft guidance for LDT. The outcome of an incorrect result for a rare
LDT is unlikely to affect morbidity, mortality or the safety of patients. 3
Research Questions
The following research questions have been proposed:
1. Can laboratories operationalize a quality management framework that will meet FDA
requirements?
2. Will an adoption of a quality system framework provide the manufacturing foundation that
will adhere to 21 CFR 820 Design Controls?

6
CHAPTER 2. LITERATURE REVIEW
This literature review will outline the history of LDT, regulatory involvement and the
current condition within the scientific community regarding laboratory-developed tests.
The Laboratory Improvement Amendment Act (CLIA) 1988 was developed and enforced under
the direction of the Centers of Medicare and Medicaid Services (CMS) and was passed to assure
the safety of the American healthcare system in general and specifically to oversee laboratory
testing. The objective of this legislation is to ensure the integrity of laboratory testing and results.
“12
Although CMS has oversight for laboratory accreditation, the Governmental Accounting
Office (GAO), conducted a study for commercially manufactured home genetic testing kits
marketed and sold to consumers that were noted to provide little medically useful information and
worst, test results “were misleading and of little or no practical use”. 4 To circumvent these issues,
two bills were introduced to allow the FDA to hold LDT manufactures to the same standard as
medical device firms. The bills were not passed and although their actions have become a source
of controversy, the FDA preemptively assumed oversight over the manufacture and regulation of
all LDT.4
Since the bills were introduced to congress, the FDA has identified problems with several
high-risk LDT that includes: “claims that are not adequately supported with evidence; lack of
appropriate controls yielding erroneous results; and falsification of data”.

5

The FDA is concerned

for patient safety and the potential outcomes of unregulated tests for a “health condition that could
result in illness or death.” 5
Although, the FDA was given oversight and authority over diagnostic testing

17

and regulate

manufacturers and devices under the Federal Food, Drug, and Cosmetic Act (FFDCA), CLIA

7
retains oversight to ensure clinical laboratories operate as described in federal regulation 21 CFR
493.
Healthcare systems aboard are vastly different. As early as 1990, the United Kingdom
instituted regulations that consisted of the establishment of clinical governance to regulate quality
systems in healthcare and to hold each organization liable for outcomes. As a result, the goal to
eliminate poor quality for the best interest of the patient is demonstrated through continuous
improvement, risk management and the establishment of processes to minimize errors. In the NHS,
all leaders are responsible for quality outcomes by managing adverse events, customer complaints,
and by ensuring that policies and procedures are implemented for all elements of the system 62
Concerns from Professional Societies
Unlike the NHS, many organizations have objected to the FDA’s oversight of LDT,
including the American Hospital Association, the American Cancer Institute (ACI), and the
American Clinical Laboratory Association (CLA). The American Medical Association has stated
“the FDA proposal will add an additional layer of regulatory requirements which may result in
patients losing access to timely lifesaving diagnostic services and hinder advancements in the
practice of medicine.” 21
The CLA has argued, “The FDA requirements would stifle laboratory innovation and retard patient
access to critical diagnostics.”

3

Moreover, the academic laboratories if held to the 21 CFR 820

standards may be required to perform clinical trials for each new genetic test developed. This
process would require additional resources and as explained by Evans, (2015) “laboratories have
insufficient resources to meet the proposed requirements and would essentially be precluded from
developing or even improving tests in response to patient needs, clinician demands and changing
technology.”

10

The perceived outcome of an innovation may influence professional groups to
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abandon processes advantageous to patient safety and Sanson-Fischer, (2004) explains “If a
proposed change alters the balance of power between or within professional groups in a “negative”
way, the innovation may not be implemented.” 22 To eliminate complexity and shorten the approval
time for new test development, the FDA is currently seeking the advice of a steering committee
that consists of multiple organizations and professional agencies to agree on a path for the best
interest of patient safety.

22

The FDA proposed framework lacks formal structure, tools

standardization and defined rules for use.
Process Standardization
A standardized harmonious approach or mandate for quality and standardization has not
been defined for US laboratories. Outside of the laboratory, many industries have adopted practices
aligned with quality standardization, however, successful implementation is based on the support
of leaders to own and drive an organic, directed initiatives with tasks and activities applied to local
specific organizational processes. As W. Edwards Deming secretary stated in a 1989 video,
“American managers would like to choose and implement quality from a Chinese menu, but there
is no instant pudding. Quality doesn't work that way.” 23
Total Quality Management
The standardization of organic processes can be found described in a 20-year-old
interpretation of a Deming management philosophy, known as Total Quality Management (TQM).
Continuous improvement, employee empowerment and standardization were at the heart of the
successful application of Deming management principles as applied to the Toyota Motor Corp.
This success story was described by academic scholars at major US institutions such as: MIT
(Womack,1990), Harvard (Spear and Bowen 1999) and University of Michigan (Liker, 2004). 30,
31, 33

Toyota’s brand of TQM came to be labeled as ‘Lean’ referring to the bufferless production
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system by a graduate student of Womack named John Krajcik (Krafcik 1988) former CEO of
Hyundai America.
Outside of Toyota, one of the best examples of an TQM initiative in healthcare was of a
new hospital CEO, Charles Evans of Memorial Hospital, Jacksonville, FL in 1991 (Case 1995)
touting TQM as key to culture change. 30 However, no subsequent publications described or were
issued by this institution. In fact, search of this hospital’s current website 22 years later shows
neither trace of that CEO nor any mention of a culture of continuous improvement, TQM, Lean or
Deming. This is typical of the archeology of TQM and is described by a (quotation-George
Santayana) “Those who cannot remember the past are condemned to repeat it.”
Continuous improvement efforts with new names continuously emerge as the flavor of the
year, however, have organizations altered their management approach to change?
As referenced by Gatchalian, 1997 the most common reasons for failure in creating successful
cultures of continuous improvement, were associated with problems of sustainability of leadership
and purpose, absence of strategic communications and teamwork for quality improvement, and
lack of total commitment to the Deming management /TQM philosophy and practice. 34 These in
turn were derived from poor understanding of the Deming philosophy by upper management and
a general lack of employee opportunities to relate training activities with company mission/vision
or directions.

35

Implementation of TQM follows an historic repetition of similar practices per

Naslund, (2008). 36 Organizations continue to re–invent the wheel, but never pause to self-reflect
on the lessons of the past. A description of this similar pattern has been described as the sevenstage life cycle of a fad for Total Quality Management and early phases of the life cycle cited by
Naslund (2008) in relation to the current enthusiasm for Lean management in healthcare.

36

The life cycle is described as follows: An academic article is written on a new discovery or theory;
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1. The study is discussed, summarized, and repeated;
2. The concept is popularized in a best- selling book;
3. Management consultants carry new techniques to their client base;
4. Managers embrace the fad and champion the concept;
5. Time passes, enthusiasm dims, and doubts and cynicism arise; and
6. New discovers occur and consultant interest turns elsewhere.
TQM did not sustain and can be seen in the trend of publications, indicating original initiatives or
the buzz, peaking in the early 1990s and then trailing off.

11
CHAPTER 3. FACING THE INEVITABLE: BEING PREPARED FOR REGULATORY
REQUIREMENTS FOR LABORATORY DEVELOPED TESTS
Overview
This chapter address an application of a standard manufacturing approach to the laboratory
is described through the application of a research design for development of a Quality Management
System titled Facing the Inevitable: Being Prepared for Regulatory Requirements for Laboratory
Developed Tests. The objective was a call for action to educate the laboratory community by
introducing terms, definitions and regulatory requirements. We discuss how these requirements
may be applicable from the medical device industry to laboratory medicine. We performed nine
interviews with laboratory professionals and as a result of the feedback developed and tested
strategic factors by use of a survey that would comprise a quality management system framework
with product development methodology to incorporate design control. This manuscript was sent
for publication in the American Journal of Clinical Pathologists.
Introduction
Contemporary technological advances in laboratory medicine have led to a category of
laboratory diagnostics known as Laboratory Developed Tests (LDTs). LDTs are defined as a
subset of in vitro diagnostics (IVDs) that are “intended for clinical use and designed, manufactured
and used within a single laboratory”.2 In recent years, the Food and Drug Administration (FDA)
identified problems with several high-risk LDT and has cited concerns that “patients could initiate
unnecessary treatment, delay or forego treatment altogether”.2 In addition to the FDA, other
governmental agencies, and private organizations have challenged the validity, accuracy,
oversight, and safety of in LDTs. The FDA has now proposed requiring “all in-vitro diagnostic
(IVD) tests intended for use in drug or biologic therapeutic decision-making be held to the same
scientific and regulatory standard” as medical device firms.2

12
Since medical device development is held to a stringent and lengthy regulatory approval
process, there is significant apprehension regarding the potential for undue delays in test
development and patient access should LDT be held to the same standard. Unlike the medical
device industry, which is subject to the requirements of the FDA, clinical laboratories are under
the jurisdiction of the Centers for Medicare and Medicaid (CMS).11 The FDA has proposed that
laboratories adopt a formal risk-based classification and approval process, Quality System
Regulation (QSR), and a formalized design control structure, as described in their 2014 draft
guidance entitled Framework for Regulatory Oversight of Laboratory Developed Tests.2 In this
draft, the FDA proposes directives that are currently not mandated by CLIA or any other regulatory
agency regarding laboratory oversight. Following a period of public comment, the Agency
announced, in a Discussion Paper dated January 13, 2017, that they were considering possible
alternatives to the original framework proposal. 6 Laboratories continue to struggle to understand
the implications of this additional regulatory oversight and their responsibility to comply in the
event the draft guidance becomes policy. Additionally, for those laboratories licensed by the New
York State Department of Health (NYSDOH), the Wadsworth Center’s Clinical Laboratory
Evaluations Program (CLEP) has recently adopted a three-tiered, risk-based review and approval
policy for all LDT submissions, effective November 14, 2016. Risk stratification is based upon an
algorithm guided by three criteria: 1) well-established methodology, 2) key determinant of care
assessment, and 3) the potential for patient impact.7 It is interesting to note that in their recent
Discussion Paper the FDA suggests the possible use of third-party collaborators, including the
NYSDOH CLEP for review of LDTs. The Agency indicates that they are “exploring accepting
NYSDOH review in lieu of its own”.6

13
Motivation for the Research
The motivation for this research is to educate the laboratory community pertinent to LDTs
by introducing terms, definitions, regulatory requirements and discuss the QSR as proposed by the
FDA. We compare the requirements of the 21 CFR 820 to the recommended Clinical Laboratory
Standards Institute (CLSI) 12 Quality System Essentials (QSE) for laboratories to understand how
these principles may be incorporated and translated into laboratory processes that align and support
the QSR. We also explore “design control” and discuss how these requirements for the medical
device industry may be applicable to laboratory testing. We conducted interviews with laboratory
professionals to gain an understanding of their concerns regarding the FDA draft guidance and
translated that feedback into operational factors relevant for the development of a robust quality
management system. Finally, we tested the factors for functionality, agility and usefulness through
a survey and propose the design of a framework to assist laboratories prepare in the event the 2014
draft guidance becomes a policy.
Contribution: This paper contributes to the discussion about LDT by serving as a proactive call
for action by educating laboratory professionals and providing the impetus to move from a waitand-see approach to insight, knowledge and clarity that encompasses the many facets of LDT. We
construct a means to collect substantiated data regarding the needs and gaps in laboratories and
propose translation of those objectives into a vocabulary familiar to laboratorians. Finally, we
translate and validate functionality and usefulness of strategic factors for design of a robust
regulatory QMS by voice of customer.
Background
The literature provides a rich background regarding the history of laboratory developed
tests. The FDA, other governmental agencies and private firms have challenged the validity,
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accuracy, oversight and safety of laboratory testing. In 2008, Genentech, a private medical device
manufacturer firm of oncologic pharmaceuticals and laboratory reagents, disputed laboratories or
other companies selling LDTs or making statements without sufficient scientific evidence to
support such claims. 8 Genentech petitioned the FDA to “require all in-vitro diagnostic (IVD) tests
intended for use in drug or biologic therapeutic decision-making be held to the same “scientific or
regulatory review”. 8
Since 2008, the FDA has identified problems with several high-risk LDTs; however, many
organizations have objected to the FDA’s oversight of LDTs, including the American Hospital
Association, the American Cancer Institute (ACI), and the American Clinical Laboratory
Association (CLA). The American Medical Association has stated “the FDA proposal will add an
additional layer of regulatory requirements which may result in patients losing access to timely
lifesaving diagnostic services and hinder advancements in the practice of medicine,” 9
Certain professional organizations argue that the FDA lacks jurisdiction over LDT’s, and the CLA
has argued, “The FDA requirements would stifle laboratory innovation and retard patient access
to critical diagnostics.” 10 Moreover, the academic laboratories if held to the 21 CFR 820 standards
may be required to perform clinical trials for each new genetic test developed. This process would
require additional resources and as explained by Evans, (2015) “laboratories have insufficient
resources to meet the proposed requirements and would essentially be precluded from developing
or even improving tests in response to patient needs, clinician demands and changing
technology.”10
The FDA was given oversight and authority over in-vitro diagnostic medical devices in
1976; however, regulatory oversight for laboratories remains with CLIA. 1, 17
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Regulatory Overview
Clinical Laboratory Improvement Amendment (CLIA)
In this section, we highlight some of the important regulations that have led to the current
framework governing LDTs. First, we discuss CLIA, next the medical device amendment, the
FDA quality system regulations and compare how those regulations differ from laboratory
accreditation.
The clinical laboratory has undergone progressive regulation over the past several decades, with
key milestones depicted in Figure 1. The current regulatory framework has evolved from the
Clinical Laboratory Improvement Amendments (CLIA) of 1967 and 1988, and is enforced under
the direction of the Centers of Medicare and Medicaid Services (CMS). The initial intent of the
CLIA 1967 amendment was to establish licensing requirements for laboratories across state lines;
however, the legislation for CLIA 88 was established to update requirements, implement
performance measures and add personnel responsibilities.

Since 1988 the amendment has

progressed to ensure validity, reliability, accuracy, and appropriateness of clinical laboratory
testing and results.11

Figure 1: Timeline of regulatory oversight
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Although the aim of CLIA is to ensure that clinical laboratories operate suitably,12 Burd
explains that CLIA lists the performance specifications as described in CFR 493 to be established,
however, “does not specify the scientific methodology or implementation tool to be used.”12 CLIA
instead defers selection of the appropriate methodology meeting these performance specifications
to the Laboratory Director’s judgement. Useful resources include not-for-profit agencies, like the
CLSI, the College of American Pathologists (CAP), and the International Organization for
Standardization (ISO), who develop and recommend clinical laboratory standards and
accreditation criteria.12 To this end, the CLSI has recommended implementation of 12 Quality
System Essentials (QSE) (Table 1) as a “framework to a systems approach to managing quality”.24
The adoption of all 12 QSE will better ensure safe testing practices that align with governmental
regulations.
Table 1: CLSI Quality System Essentials 24
1.

Organization

7.

Process Management

2.

Customer Focus

8.

Documents and Records

3.

Facilities and Safety

9.

Information Management

4.

Personnel

10. Nonconforming Event Management

5.

Purchasing &Inventory

11. Assessments

6.

Equipment

12. Continual Improvement

Medical Device Amendment
The medical device amendment was established in 1976 after 4.5 million Dalkon Shield
intra-uterine devices sold between 1971-1974 adversely affected 900,000 women in the USA.25
This device considered faulty was the impetus that promoted the establishment of FDA regulatory
oversight to ensure the effectiveness of the intended use of medical device and to verify safe
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manufacturing practices. The amendment required three classifications of medical devices: Class
I- Low Risk medical devices; Class II- Moderate Risk; and, Class III- High Risk. The regulatory
approval process differs significantly for each class of device. Class I devices require General
Controls, Class II devices require pre-market notification (510(k)), and Class III devices require
the most rigorous process of pre-market approval (PMA). These classifications of medical devices
have not been a concern for diagnostic laboratories until the FDA’s announced 2014 Draft
Guidance for LDT. 26
Quality System Regulation [21 CFR 820]
The 21 CFR 820 or Quality System Regulation (QSR) is a regulatory requirement that
directs the methods for the design, manufacture, packaging, labeling, storage, installation and
servicing of medical devices to ensure their safety and efficacy.

2

The QSR encompasses

organizational structure, management responsibilities, procedures, processes, and resources for
establishing and maintaining a quality management system and serves as a guide for organizations.
The 2014 LDT draft guidance proposes the use of this existing QSR. However, LDTs differ from
medical devices in three respects: 1) LDTs are considered by most outside of the FDA to be a
medical service, not a device; 2) medical devices may be tested on human subjects and approvals
may require additional time, processes, resources and regulatory requirements 3) Under the FDA,
a device manufacture must demonstrate safety and efficacy of the product and may require
verification through clinical trials for a (PMA) premarket approval for new devices or substantial
equivalence for a (510K) predicate device. 1
Differentiation Between Laboratory Developed Testing and Medical Device: Devices
Cleared
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The FDA cleared 2957 medical devices as 510(k) in 2012.27 The average approval time for
FDA internal review in 2012 was 168 days. As of September, of 2012 the FDA received 2965
devices, of which, 1715 were rejected with a refusal rate of 58%.28
In comparison, CLIA requires that tasks, activities and processes of diagnostic testing show
accuracy and reliability of testing confirmed by validation of parameters and results. The FDA
clinical trials are not equivalent to CLIA validation of testing parameters.
Similar to CLIA, the FDA does not provide the operational design template, detailed instruction
or translation from medical device requirements essential for interpreting, extrapolating, designing
and implementing a QSR
Table 2: Medical Device Requirements Regulation 26
21 CFR 820 Quality System Regulation (QSR): Quality
System Regulation requirements
ISO 13485: International Standard- Regulatory Quality
Management System Requirements for Medical Device
Good Manufacturing Practices (GMP): Guidelines for
manufacturing, testing, and quality assurance to ensure that a
product is safe for human or animal consumption or use
Good Laboratory Practice (GLP): Principles to assure the
quality and integrity of non-clinical laboratory studies

Comparing QSE to QSR
Parallel to the QSR, the 12 QSEs contain most of the broad management categories and
elements found in the 21 CFR 820 (Table 3 is a side by side comparison of QSE to QSR, showing
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where they are equivalent and how they differ.).

41

However, the extent of their applicability to

laboratories differ. Without a step-by-step guide for establishing the operational structure required
to comply with the QSR, laboratories may feel they lack the resources and funding to develop a
quality management program that meets FDA specifications.
Table 3: Quality System Essentials in comparison to 21 CFR requirements
12 Quality System Essentials (QSE)
Organization

21 CFR 820 Quality System Regulation (QSR)
Management Responsibility

Customer Focus
Facilities and Safety
Personnel

Personnel

Purchasing and Inventory

Purchasing Controls

Equipment
Process Management

Process Controls
Production and Acceptance Activities
Design Controls
Identification and Traceability

Document and Records

Document Controls

Information Management
Nonconforming Event Management

Nonconforming Product

Assessments

Quality Audit

Continual Improvement
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21 CFR 820: Understanding Design Control
“Design Control” was originally established as a guiding methodology for the design,
development, manufacture and production of medical devices to ensure accuracy, reliability and
quality are consistently built into every new device. The elements of 21 CFR 820 Design Control
provide the manufacturing expectation of the FDA to produce a safe and effective product. 29 This
methodology is an iterative process similar to product development methodology and although
historically intended as a requirement for medical devices, the development of policies, procedures
and processes as applied to test design should help with the establishment of design control specific
to the laboratory. Figure 2. lists each element of design control from development to design history
and Table 4 lists each element of design control with a modified description for the practical
application to organizational processes. (Appendix C.)
Design &
Development

Design
Input

Design
Output

Design
Review

Design
Verification

Design
Validation

Design
Transfer

Design
Changes

Design
History

Figure 2: Elements of Design Control for LDTs (21CFR 820)
Table 4: Description of Design Control 29
21 CFR Design

Description

Control
Design and

Procedure: Set of processes that transforms requirements for an object

Development

into more detained requirements. Such as the plan, design, development,

Planning

execution, involvement and interface with different groups and
responsibility (ISO 9001)

Design Input

Procedure: Product characteristics, requirements, intended use, user
needs and the process to manage and resolve discrepancies is defined.
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The process includes, responsibility approval, documentation and rational
at every step
Design Output

Procedure: The output consists of technical, performance, specification
and verification that the design successfully transferred into the testing
environment

Design Review

Procedure: Describes the process to review all phases of the design with,
documentation and approval all at each step. Establish and maintain
procedures for the identification, documentation, and validation,
verification, review, and approval of design changes before
implementation

Design *

Procedure: Describes the process that will ensure the test is safe,

Verification

effective for use, conforms to the needs of the user and meets its intended
use. The process to ensure the design works as intended, has been
verified, documented and approved at each activity

Design

Procedure: The process operates as intended under defined operating

Validation

conditions

Design Transfer

Procedure: Describes the process of accurate transfer of the design into
manufacturing requirements

Design Changes

Procedure: Describes the process to identify, track, document and
approval changes prior to each activity

Design History

A means to track processing information pertaining to design,
development, testing and links with all other design controls to
demonstrate traceability and approval for each LDT manufactured
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Medical Device

Procedure: Describes the process to identify, document and report an

Reporting (MDR) adverse event as an outcome of the test

*NOTE: Verification pertaining to Design Control and Validation host two separate meanings in
the laboratory. 37
Verification: Confirmation, through the provision of objective evidence, that specified
requirements have been fulfilled. (design output meets the design input requirements)
Validation- Confirmation through the provision of objective evidence, that the requirements for a
specific intended use or application have been fulfilled. 37, 38
Research Methodology
Now that we have covered the regulatory background, we turn to the technique conducted
in this study as a mixed method approach to research employed in two sequential phases: Phase I
consisted of qualitative interviews to capture the understanding of laboratory professionals in all
aspects of LDTs and to determine if adherence to FDA regulatory requirements was achievable in
a laboratory environment to design, develop, and test LDTs. If not, why not, and what would be
the limiting steps.
In addition to the interviews, proceedings from the 2 Day FDA Work shop “Framework
for Regulatory Oversight of Laboratory Developed Tests(LDT)”
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held January 8-9, 2015 also

contributed to this study. The intent of the workshop was for the FDA to provide the rationale for
the 2014 draft guidance, invite feedback and participation from peers within the laboratory
community to state their case for or against the 2014 framework in context of the proposed
regulatory requirements. The interview and workshop information assisted the researchers identify
factors that would serve as the building blocks for a regulatory laboratory framework.
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During Phase II a quantitative survey was conducted to test the factors identified during
the interviews to determine agility, functionality, and usefulness as a proxy in the absence of
implementation in a live environment.
The study was designed as follows:
Phase I – Interview: A qualitative phone interview protocol was designed based on results of a
review of the literature and was initially conducted to explore the potential challenges and
constraints for laboratory compliance to the 2014 draft guidance. A convenience sampling strategy
was used to select subject matter experts well versed in the historic, political and practical
perspective of LDTs. The nine interview participants selected were professionals from the fields
of laboratory, regulatory, accreditation, and medical device segments of the industry and who had
the time or the availability to participate.

(Appendix A.) The names of the interviewees and

associated organizations are retained as confidential.
Secondary Data: The presentations obtained from the 2015 2 -Day FDA Work shop as it pertains
to Quality System Regulation was documented, described and incorporated in this research. The
public workshop was particularly helpful for this research and clarified issues and concerns as well
as provided insight about future regulatory direction, strategy, and explained how FDA
recommendations may affect future laboratory operations.
Constructing the Interview Protocol
The interviewees were asked the questions in the following protocol and were encouraged to
discuss their knowledge of LDTs. The 30-minute confidential interview protocol consisted of nine
questions (Table 5). (Appendix B.)
Table 5: Interview Questions
1. What is your role, title, and responsibility in the organization?
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2. Tell me about the history and your knowledge about of Lab developed Tests?
3. What are some of the regulatory challenges associated with LDT’s?
4. How does genetic testing influence regulatory oversight?
5. Describe the current scrutiny associated with regulatory guidelines for LDT’s?
6. What is the role of the FDA in lab developed tests?
7. Explain the intent of the FDA guidance framework for LDT’s released December
2014?
8. In your opinion, what would the implications(s) be if the FDA mandated regulatory
guidelines for the process of LDT’s?
9. How would you describe the “outcome and view of the future” if the FDA mandates
regulatory oversight for LDT’s?
Data Collection
The interviews were conducted by telephone over a two-year period from April 2015-May
2017. The process was explained prior to the interview, was audio-recorded when possible, and
the results compiled. In addition to interview data, secondary data was collected from discussions
that pertained to the quality system regulation during the public workshop to capture concerns with
the 2014 draft guidance.
Data Analysis
The interviews were conducted with nine participants and the discussions were manually
transcribed. The topics of the conversations were tallied for frequency and coded manually. As
depicted in Table. 7 the interview and secondary data were categorized into codes and sub-codes,
and a relational analysis was conducted to identify patterns of the most frequent theme and trends
in both the interviews and the workshop discussion.
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Phase II Survey: Testing the Functionality of the Framework
Constructing the Survey Protocol
A confidential Qualtrics Survey consisting of three sections was developed for this study.
Section I includes survey statements derived from extensive literature searches, the qualitative
interviews and a review of the 2015 2 - day FDA workshop pertinent to the QSR on Laboratory
Developed Tests. Based on feedback, we translated the findings into a taxonomy comprised of
eight strategic factors and 40 statements that serve as building blocks for a laboratory regulatory
quality management system. As depicted in Appendix G, each statement contains five statements
totaling 40 outcomes ranked on a 5 point Likert scale from “extremely important” to “not important
at all”.
The strategic factors identified are as follows:
1. Leadership commitment
2. Training
3. Pre-assessment of the current QMS
4. Design Control
5. Document Control
6. Process Control
7. Development of a QMS framework
8. Process validation
Section II contained two open-ended questions regarding the functionality, agility and usefulness
of the strategic factors listed in the study. The feedback was instrumental in determining if the
participants agreed with the factors included in the survey or in assessing their opinion about what
factors would be more appropriate.
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1) Do you agree with the strategic factors identified in the proposed framework for a Quality
Management System of LDTs? If not, please suggest additional factors pertinent to develop a
robust framework
2) Do you think the establishment of a Quality Management System framework will assist LDT
laboratories incorporate regulatory requirements such as design control more readily? If not, why
and what else is necessary?
Section III included two questions to substantiate the understanding of the respondents regarding
LDT design, development, validation and delivery in a laboratory environment, and to document
their professional role. The questions were as follows:
1. What is your professional role?
a. Senior leader
b. Medical Director
c. Medical Doctor
d. Technical Supervisor
e. Manager/Supervisor
f. Quality Professional
g. Other
2. Do you consider yourself a subject matter expert on the topic of LDT?
a. Definitely yes
b. Probably yes
c. Might or might not
d. Probably not
e. Definitely not
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Data Collection
The quantitative survey was distributed to 767 laboratory professionals from April- July,
2017. The respondents included all attendees from the Executive War College Laboratory
Conference held in May 2017 in New Orleans, LA. The survey was also distributed to randomly
selected laboratory professionals demonstrating expert knowledge regarding the field of LDTs
from LinkedIn with titles in the fields of regulatory, quality and medical laboratory.
Survey Demographics
The responses from the Qualtrics survey resulted in 51 started surveys and 35 completed
surveys with a 69% completion rate of those who responded to the survey. The respondents
included 10 senior leaders, four medical directors, 13 quality professionals, two technical
supervisors, one manager and five other professionals. To ensure the appropriate expertise in the
field of LDTs each participant was asked a critical qualifying question: Do you consider yourself
a subject matter expert in the topic of LDT? Nine participants responded, “Definitely yes”, nine
“Probably yes”, six “Might or Might not”, seven “Probably not” and two “Definitely not” as
depicted in Table 6.
Table 6: LDT Expert classification of survey respondents

28
Data Analysis
The statistical software SPSS Version 24 was used to calculate and analyze the scores for
significance across all eight factors and 40 statements. The descriptive statistics include the mean,
standard deviation and variance. Additional statistical analyses are as follows:
Principal Axis Factoring extraction method
The data was further analyzed by the Principal Axis Factoring extraction method, more
specifically Principal Component Analysis with the Rotation Method: Varimax with Kaiser
Normalization. According to Williams, (2010) isolating factors with high loadings can reduce the
variables into a smaller set of factors, remove variation and cluster the relationships into patterns.
This method was helpful to identify patterns consisting of high loadings with significant factors
and statements exceeding 0.623 as depicted in Table 9. 40
T-Test
The T-test was performed to determine whether the means of experts and non-experts had
distinct, differing priorities and were statistically different regarding the adoption of a QMS. Since
the participants rated four of five factors within the leadership commitment as the most relevant
category, the assumption was the experts may have answered the statements differently due to
their roles and responsibilities within the organization. The non-experts were operationally
oriented rather than occupying a leadership role. To test this assumption, the data was analyzed to
determine if experts and non-experts chose statements within the eight strategic factors differently.
Open –ended questions
The responses to the open-ended questions were analyzed using SPSS Version 24 to
determine the number of participants considered an expert (Table. 6) and to tally acceptability and
satisfaction with the suggested factors as explained in the survey results section.
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Results
Interviews
The tone expressed by the interviewees was ambiguity and uncertainty regarding all
aspects of the LDT process and similar concerns were articulated, including: 1) risk classification,
2) process validation to ensure the accuracy and precision of tests results, 3) the ambiguity of the
21 CFR 820 requirements translated to the laboratory 4) lack of clarity from the FDA and other
governmental agencies (e.g., CMS) 5) the patient safety concerns of the FDA 6) lack of clarity and
direction regarding the 2014 draft guidance.
The lack of coordination, clarity and guidance from CLIA and the FDA has created
confusion and a lack of motivation on behalf of the laboratory community. The general feedback
received through the interviews showed substantial ambiguity across laboratory professionals
regarding terms, definition and how to transfer operational requirements into regulatory terms. In
addition, it is unclear how the draft guidance would translate from medical device to the laboratory.
The development of a laboratory application of 21 CFR 820 quality systems regulation that would
meet the LDT manufacturing requirements has not been addressed by regulatory agencies and has
left laboratory leaders unprepared to be proactive. Ambiguity also existed during the interviews
regarding the definition of design control and how to appropriately address and translate these
requirements into the laboratory environment.
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Interview Results
13
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7

5
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FD-PV

FD-CFR

GEN-UCT

GEN-PT

FD-FRW

LAB-ACC

LAB-QS

ACC-CLA
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Figure 3: Interview Results
The discussion with the interviewees was instrumental to gain an understanding of the
challenges faced by laboratory leaders, accreditation agencies and regulatory policy makers. The
interview findings depicted in Figure. 3 illustrates the basis for the development of an operational
framework for LDT. (Appendix F.)
The top 5 most significant concerns are identified as follows:
1. FD-RC: Risk Classifications
2. FD-PV: Process Validation
3. FD-21 CFR 820 QSR Requirements
4. GEN-UCT: Uncertainty
5. GEN-PT: Patient Safety
Table 7: Leading Interview Codes
Code

Category
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General
GEN- HT

History of LDTs

GEN- TN

Technology

GEN- PT

Patient safety concerns

GEN-DIR

The laboratory need for direction

GEN- BM

Change business model

GEN-UCT Uncertainty of requirements and path forward

LAB
LAB-Org

Hardship to organization

LAB-ACC Accreditation requirements
LAB-QS

Quality Management Systems

FDA
FD-RC

Risk classifications

FD-PV

Process validation

FD-FRW

FDA 2014 Framework proposal

FD-OS

Outsource may be necessary

FD-RS

Resources are needed to comply with regulations

FD-CFR

21 CFR 820 QSR requirements

Secondary Data
FDA Public Workshop

32
The information shared during a 2 day FDA webinar held January 8-9, 2015 made a
significant contribution to this research. 39 The FDA began the conference by addressing areas of
concern regarding the overview of LDTs draft guidance and the implication of adverse test results
for the patients and the laboratories, and how the guidance would affect regulatory agencies
already lacking appropriate resources. The director of the Centers for Devices and Radiological
Health Jeffrey Shuren, stated that the “FDA is transparent and does not claim they got it all right
and some say they didn't get anything right”. However, the FDA is acting on the behalf of patient
safety, which has made its way into the popular press.

39

In fact, Adverse patient safety concerns

associated with LDT was published in literature: New York Times Aug. 28, 2008, July 7, 2011
and January 22, 2011.

39

Guest speakers shared their support and apprehension of the draft

guidance and addressed the importance of test accuracy for appropriate therapies. Katherine
Tynan, (2015)

39

a presenter stated “Quality systems vary significantly in terms of scale and

complexity, and one of my concerns with the current dialogue between the FDA and laboratories
developing LDTs is that quality means very different things to the stakeholders”.
Research and Development firms stressed the importance of laboratories outside of
manufacture to be held to the same regulatory oversight and stated that a major cause of the
inaccuracies of laboratory test development is improper design and lack of validation to verify the
result is as intended. This topic was substantiated by consistent feedback mentioned 12 times from
all nine interviewees also expressing test validation concerns. Liz Lison, president of Advocea
Consulting firm (2015) and a conference speaker explained, “Most of the failures that I have seen
in LDTs may have been averted if design controls had been in place. Therefore, I urge the agency
not to delay the enforcement of design controls for high-risk tests and potentially introduce a two
-tier system for pre-market review.” 39
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The oversight of laboratory testing remains with CLIA. However, a gap exists regarding
the regulation of test development. Due to the advances in genomic medicine the interviewees
expressed that the oversight by CLIA is no longer adequate to manage the compliance needs of
laboratories. There is a significant difference in the oversight of the FDA and CLIA. The FDA
does not mandate the operation of testing as stated in CFR 493; CLIA does not ensure the safety
and effectiveness of test protocols as described in 21 CFR 820 41
Results
Secondary Data
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Figure 4: Secondary Data Results
Interpretation of Findings
The interview and secondary findings validated the motivation for this study.

The

laboratory professionals illustrated the struggle to understand how to develop and organize a
framework adaptable to their organization. The participant response from the 2-day work shop
was more directive and outlined the need of laboratories versus the uncertainty noted during the
interviews. As a result, the participants substantiated the need for a regulatory vocabulary
translated to operational laboratory terms. In addition, the feedback describing gaps in processing
was instrumental to the development of strategic factors developed from interview and workshop
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feedback and proposed as the precursor to a quality systems framework that would serve as the
foundation for LDT development as depicted in Table 8:
Table 8: Suggested strategic factors necessary for a regulatory QMS framework 44
Strategic Factors
developed as a
Topic

Interview/Conference Discussion
result of the
interviews

Interview

Leaders are unclear regarding how 21 CFR 820

Leadership

Topic

requirements applies to laboratory testing considered by

Commitment

many to be a service, not a product.
Interview

Laboratories lacked the rigor that is present in the

Topic

manufacture of medical devices.

FDA Public

It is essential that FDA harmonize the QSR requirements

Pre-assessment of

Workshop

with CLIA requirements at a more granular level to

the existing

prevent duplicate efforts and to ease the regulatory

Quality

burden” because governmental agencies have not provided

Management

the necessary guidance for struggling laboratories

System

FDA Public Laboratory failures due to lack of process control

Training

Design control

Workshop
FDA Public Change is necessary to raise the level of quality, prioritize
Workshop

tasks and dedicate the time and resources necessary to
understand regulatory requirements in order to attain
process standardization.

Document control
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Interview

The major cause of the inaccuracies of laboratory test

Topic

development is improper design and lack of validation to

Process control

verify the result is as intended.
FDA Public Laboratories need a guidance documents and a defined

Development of a

Workshop

process to simplify and translate FDA proposal

QMS framework

Interview

The importance of test systems to validate protocols,

Process Validation

Topic

processes and test development that will consistently
ensure the effectiveness and accuracy of test results

Survey Results
Exploratory Factor Analysis and Factor Reliability
The factor analysis was conducted to explore the data set, determine the importance of the
relationships between the variables and isolate the factors with high loadings to reduce variables
into a smaller set of factors. As described by (Williams, et al, 2010) an appropriate factor load of
0.50 is optimal for factor analysis. However, due to the smaller sample size a significant factor
loading would be 0.60 or larger. 40 The analysis eliminated 17 variables with smaller loadings as
shown in Table 9. The loadings analyzed and clustered the relationships into patterns. The clusters
illustrated the importance of leadership, clinical validity, process validation, and procedures to
provide guidance for accuracy and consistency of processes. The weak factors removed clarified
the reluctance to perform a pre-assessment of the existing operation to determine if the
organization was prepared to operate within a regulatory environment.
Table 9: Exploratory Factor Analysis and Factor Reliability performed on each category
Rotated Component Matrixa
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Statement Statement Description

Component
1

Q2_4

Staff training

0.822

Q3_3

Crosswalk of current

0.772

processes
Q3_5

Clear understanding of 0.701
QSR requirements

Q2_5

The assignment of

0.691

responsible persons
Q7_3

Pre-assessment of

0.635

current processes
Q5_4

Documentation of tasks 0.626
and activities at each
step

Q2_3

The program includes

0.614

value stream mapping
to demonstrate the
significance of handoffs
Q3_2

ISO 15189 will assist
the organization
comply to requirements

Q7_4
Q7_5

0.612

2

3

4

5

6

7

8

9
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Q6_4

Clinical validity is

0.811

performed as validation
Q6_3

Documentation of

0.765

analytic validity will
demonstrate accuracy
and reliability
Q6_1

Responsibility for every

0.615

handoff to ensure LDT
accuracy
Q1_3
Q5_5
Q8_3

Process qualification

0.871

ensures design
specification
Q8_2

Validation to ensure all

0.779

steps meet regulatory
requirements
Q8_4

Operational
qualification will
ensure the process is
operating as intended

Q7_1

0.675
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Q5_2

Clearly written

0.859

procedures remove
ambiguity in the
process
Q5_1

Updated and accurate

0.761

operating procedures
Q1_4
Q3_1
Q8_5

Performance

0.696

qualification produces
the same result and
operates correctly
Q2_1

Training includes

0.659

introduction to LDTs
Q8_1

Process validation is

0.626

performed to ensure
effectiveness
Q2_2
Q1_2
Q4_3

Design control well
implemented and
documented will ensure
quality

0.759
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Q4_2

Design control

0.724

described in laboratory
terms will clarify
requirements
Q7_2
Q4_4
Q6_5

Data collection and

0.863

clearly communicating
requirements
Q6_2

The consistent

0.764

uninterrupted flow of
material will
demonstrate user
friendliness of the
framework
Q5_3
Q1_1

Leadership institutes

0.699

key performance
indicators
Q4_5

A procedure that
address adverse events

Q3_4
Q4_1

0.665

40
Q1_5

Leadership consistently

0.734

communicate change

Extraction Method: Principal Component Analysis. Rotation Method: Varimax with Kaiser
Normalization.
a. Rotation converged in 15 iterations.
Over all Mean of Categories
To determine if factors were viewed differently by experts versus non-experts the
aggregate mean for the items associated with each factor was analyzed. As sown in Table 10,
experts versus non-experts chose similar responses for all statements within the survey from an
average of close to one – extremely important to slightly over two- very important. This result
suggests both groups considered all factors to be equally important for the development of a QMS.
(Appendix. VII)
Table 10: Over all Mean of Factors
Descriptive Statistics
N

Range

Minimum

Maximum

Mean

Std.
Deviation

Variance

AverQ3_Preassess

33

2.40

1.00

3.40

1.9515

0.58101

0.338

AverQ4_DesignContrl

33

2.20

1.00

3.20

1.9455

0.60472

0.366

AverQ5_DocuentContrl

33

2.00

1.00

3.00

1.9030

0.58335

0.340

AverQ7_Development

32

1.80

1.00

2.80

1.8844

0.42435

0.180

AverQ6_ProcesContrl

32

1.60

1.00

2.60

1.8453

0.45497

0.207

AverQ2_training

33

1.40

1.00

2.40

1.8364

0.40452

0.164

AverQ8_ProcessValid

33

1.80

1.00

2.80

1.7212

0.48718

0.237

AverQ1_Leadership

33

1.20

1.00

2.20

1.5333

0.32275

0.104

Valid N (listwise)

32

T-Test Factor Analysis
As shown in Table 11, the mean responses to the factors by experts versus non- experts.
The hypothesis was experts and non-experts had different and distinct priorities regarding adoption
of a QMS due to their roles and responsibilities within organization and may have answered
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statements differently. We found that there was no significant difference between experts and
those of non-experts on average importance attributed to the strategic factors.
Findings: No significant difference between the responses of experts and non- experts.
Table 11: T-Test Results
Levene's Test for
Equality of Variances

AverQ1_Le Equal
adership
variances
assumed
Equal
variances
not
assumed
AverQ2_trai Equal
ning
variances
assumed
Equal
variances
not
assumed
AverQ3_Pr Equal
eassess
variances
assumed
Equal
variances
not
assumed
AverQ4_De Equal
signContrl
variances
assumed
Equal
variances
not
assumed
AverQ5_Do Equal
cuentContrl variances
assumed
Equal
variances
not
assumed
AverQ6_Pr Equal
ocesContrl variances
assumed
Equal
variances
not
assumed
AverQ7_De Equal
velopment variances
assumed
Equal
variances
not
assumed
AverQ8_Pr Equal
ocessValid variances
assumed
Equal
variances
not
assumed

F
1.026

0.082

0.032

0.293

0.928

1.221

0.003

0.901

Sig.
0.321

0.777

0.859

0.593

0.345

0.280

0.958

0.352

Independent Samples Test
t-test for Equality of Means
Sig. (2Mean
Std. Error
tailed)
Difference Difference
0.798
-0.03333
0.12910

t
-0.258

df

-0.280

19.907

0.783

-0.03333

0.543

25

0.592

0.572

18.466

0.504

25

95% Confidence Interval
of the Difference
Lower

Upper

-0.29922

0.23255

0.11921

-0.28208

0.21542

0.08889

0.16366

-0.24818

0.42596

0.574

0.08889

0.15549

-0.23718

0.41496

25

0.619

0.12222

0.24273

-0.37769

0.62214

0.528

18.308

0.604

0.12222

0.23135

-0.36324

0.60768

-0.946

25

0.353

-0.24444

0.25843

-0.77669

0.28780

-0.886

13.663

0.391

-0.24444

0.27581

-0.83737

0.34848

-0.828

25

0.415

-0.20000

0.24148

-0.69733

0.29733

-0.893

19.659

0.383

-0.20000

0.22406

-0.66790

0.26790

0.088

24

0.931

0.01667

0.18916

-0.37374

0.40708

0.100

18.558

0.921

0.01667

0.16651

-0.33240

0.36574

-0.310

24

0.759

-0.05556

0.17922

-0.42545

0.31434

-0.327

15.388

0.748

-0.05556

0.16980

-0.41669

0.30558

-0.272

25

0.788

-0.05556

0.20443

-0.47659

0.36548

-0.244

12.335

0.812

-0.05556

0.22808

-0.55100

0.43989

Survey Results: Expert Response per Quartile
The survey results for the most important rated statements with corresponding means as
depicted in Figure 5. begins with Leadership Commitment as described for statements, one, two,
three and five. (Appendix F.) The commitment of leadership to institute key performance
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indicators, direct regulatory initiatives and maintain and consistently communicate change in the
organization was considered significant. However, a poorly rated statement was the task of an
organizational pre- assessment to determine missing processes, lack of procedures, deficiencies
and create a list of necessary guidance documents to comply to regulatory requirements. This
outcome was unanticipated due to laboratory accreditation agency practices of a cross walk
between laboratory current processes in comparison to requirements. Statements depicting design
control were not considered extremely important with all five statements located on the second,
third, and fourth quartile, despite the proposal for QSR by the FDA. There were no significant
results for the following statements: 1) the statement suggesting a procedure to address the process
for identification, documentation and reporting of an adverse event in the laboratory and the 2)
establishment of an LDT quality committee to quickly approval changes and provide support.
Respondent Feedback
The open -ended questions presented to the survey respondents in Q9, Do you agree with
the strategic factors identified in the proposed framework for Quality Management System of
LDTs? If not, please suggest additional factors pertinent to develop a robust framework. This
question resulted in positive feedback for the development of a QMS framework and 20 of 35
participants agreed with the strategic factors proposed by the researcher. The respondents agreed
that all the factors and statements listed were indeed important. However, leadership buy in was
considered imperative for implementation and to ensure the proper resources to address
development of the QMS.
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Q1
Leadership
Commitment
Mean
1.28
1.3
1.33
1.39
1.44
1.5
1.56
1.61
1.67
1.67
1.71
1.72
1.78
1.82
1.83
1.89
1.89
1.94
2
2.06
2.17
2.22
2.28

Q2
Training

Q3
Pre
assessment of
exsisting QMS

Q4
Design
Control

Q5
Document
Control

Q6
Process
Control

Q7
Development
of a QMS
Framework

Q8
Process
Validation

Statement
Q1_5
Q1_1
Q1_2
Q1_3

Q1
Q6_4
Q8_3
Q7_1
Q2_2

Q5_5

Q8_2

Q6_3

Q4_3

Q8_1
Q8_4
Q7_5

Q3_5

Q4_1

Q2

Q5_1
Q5_2

Q8_5
Q6_1

Q2_5

Q7_3
Q3_2

Q4_2

Q7_2

Q3

Q4_4
Q2_1

Q3_1

Q5_4

Q2_4
Q1_4

Q6_5

Q2_3

Q5_3

Q7_4

Q6_2

Q3_3

Q4

Q3_4
Q4_5

Figure 5: Quartile split of Survey Statements by Expert Participants
Feedback- The Establishment of a Quality Management System Framework
The question presented to the survey respondents in Q10 - Do you think the establishment
of a Quality Management System framework will assist LDT laboratories incorporate regulatory
requirements such as design control more readily? If not, why and what else is necessary? Out of
35 respondents 23 answered this question with yes, I agree and strongly agree and nine of 35
respondents scripted favorable feedback. The respondents agreed that a fully functional QMS is
needed to meet accreditation requirements and document control is critical in this process. An
accepted framework will provide the laboratory community “structure, uniformity and integrity”
(survey respondent) and the documentation discipline for all laboratories. The process is not only
beneficial for the development of LDT but in the general lab as well to comply with accreditation
requirements. A crosswalk of each clause of Part 21 CFR 820 can be performed in comparison to
the elements of each QSE. The QSE can be used as the QMS framework; however, the most
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difficult topic discussed in the draft guidance is clinical significance and how the results derived
from a LDT are being used or will be used to guide therapy.
Discussion
The impetus for change within the laboratory community began with the awareness of
patients that were adversely affected by the results of a Laboratory Developed Tests. Historically
the design and development of LDTs was not under the jurisdiction of CLIA and testing operations
are formally not within the oversight of the FDA. Many articulated the FDA has no jurisdiction
over LDTs. In addition, before synergistic legislation can occur the agencies must bridge the gap
between required regulations. Shelia Walcoff of Goldbug Strategies (2015) and a FDA Work Shop
speaker stated that “It is essential that FDA harmonize the QSR requirements with CLIA
requirements at a more granular level to prevent duplicate efforts and to ease the regulatory
burden” because governmental agencies have not provided the necessary guidance for struggling
laboratories.

39

The adoption of a laboratory structure that would satisfy accreditation and

regulation requirements in the event the 2014 draft guidance becomes a policy is perplexing. The
interviewees expressed that laboratories may be required to change business strategies, outsource
or terminate many of the current tests if the FDA proposal becomes a policy.
However, interviewees also expressed that laboratory leaders are taking the wait-and-see
approach because the laboratory community considers test development a service, not a product.
The interviewees shared their concerns for CLIA and the FDA to collectively develop standards
and guidance documents prior to a policy release.

The current regulations for medical device

include requirements for design control geared for product development and the meaning of design
control, methodology and the translation of these regulations from the medical device industry to
a clinical laboratory do not exist. The survey respondents agreed that a regulatory oriented
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framework for the development of LDTs is needed in the laboratory and it is interesting to note
that the survey respondents did not consider design control as extremely or very important despite
the proposal for a QSR by the FDA. These findings support the conclusion of ambiguity
interpreting the meaning of design control and how this requirement would be adapted to the
laboratory environment. Liz Lison, president of Advocea Consulting firm (2015) and a FDA Work
Shop speaker explained, “Most of the failures that I have seen in LDTs may have been averted if
design controls had been in place. 39
The eight suggested strategic factors and 40 statements derived from the literature,
qualitative interviews and the FDA work shop provide the impetus for design of an QMS. The
respondents agreed with all statements relevant to the design of a QMS based on needs and gaps
expressed by laboratory professionals. This finding aligns with the results of the survey as there
was no significant difference in the way the experts verse non- experts responded to factors and
associated statements. All respondents chose statements as 1) extremely important or 2) very
important.

This finding directly aligns with the recommendation by Katherine Tynan, an

independent regulatory consultant from the 2015 FDA workshop that offered advice to
governmental agencies as follows:
1. “Develop a common vocabulary that laboratories can understand”
2. “Simplify the cumbersome QSR and assist laboratories translate the directives”
3. “Develop a “QSR fit for purpose and harmonize the standard”
Tynan’s advice to laboratories was to “invest in a quality management system, implement all
factors of design control, and be proactive and prepare for future regulatory requirements.” 39
Consequently, the preparation of a QMS require the understanding of where gaps exist to
develop appropriate processes that would to adhere to requirements. Moreover, this survey
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statement suggesting review of current policies and procedures to identify gaps was not considered
important by all groups. This was an interesting conclusion because this is general practice within
laboratory accreditation agencies.
The future research includes design of an agile, robust quality management system that
will incorporate the suggested factors as follows:

leadership commitment, training, pre-

assessment, design control, document control and development of a QMS framework.
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CHAPTER 4. DESIGNING A REGULATORY AGILE QUALITY MANAGEMENT
SYSTEM FOR DEVELOPMENT OF LABORATORY DEVELOPED TESTS
Change will not come if we wait for some other person or some other time. We are the ones we've
been waiting for. We are the change that we seek. -Barack Obama
Overview
This chapter continues the call for action by assisting leaders to prepare for a regulatory
QMS. We address the concerns of the laboratory community and discuss the current position of
regulatory agencies. Our premise is to prepare, because this issue holds the likelihood to effect
patient safety and as expected, may not go away. We provide step by step instruction to design a
QMS. This manuscript was sent for publication in the American Journal of Clinical Pathologists.
Introduction
The position of the Federal Drug Administration (FDA) for the oversight of laboratory
developed tests has evolved since the issued 2014 draft guidance entitled Framework for
Regulatory Oversight of Laboratory Developed Tests.2

This 2014 draft guidance proposing

oversight for laboratories that manufacture in house LDT was fully supported by physicians,
pharmaceutical firms, IVD manufactures and insurers, however, received significant objection and
opposing public opinion by the laboratory community.42 To neutralize public opinion, the FDA
published a discussion paper dated January 13, 2017 and some claim the oversight by the FDA
may be on hold, however, Gatter, (2017) has stated “it is unlikely that the issue is over”. 42 In fact,
in a January 13, 2017 discussion paper the FDA indicates support for CLIA requirements
regardless of the dissimilarity to 21 CFR 820 Quality System Regulation (QSR) requirements. The
paper describes three QSR recommendations “consistent with the approach described in the
discussion paper” 6 for laboratories that develop LDTs. These quality system regulations address
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requirements for test development not mandated by CLIA regulations: These requirements
include:
1. Design Control – “an interrelated set of practices and procedures that are incorporated into
the design and development process, i.e., a system of checks and balances and make
systematic assessment of the design an integral part of development” 5
2. Acceptance Activities – “adherence to requirements through inspections, assessments, or
other verification” 41
3. Corrective and Preventative Action – The process to investigate the cause of occurrences
in the lab to ensure documentation, correction and follow up is performed.41
This recommendation, if implemented will constitute a proactive approach to process
standardization and compliance to the adoption of a QSR framework.

However, many

laboratorians are unclear “how to” interpret, extrapolate, design and implement a QSR and the
instruction has not been provided. In addition, laboratories are unclear how the framework written
from a medical device perspective can relate to diagnostic laboratories. 44 Furthermore, to the 12
Quality system essentials, the nonexistence of a template, guidance document or standard approach
to development of a quality management system (QMS) aligned with accreditation requirements,
has resulted in “various levels of quality” within laboratories.12 Laboratories resort to reinventing
the wheel or adopt practices aligned with process standardization such as the implementation of
ISO 9001, ISO 17025 and ISO 15189 specific to medical laboratories.12

Although, these

documents provide guidance, the successful implementation of process standardization is based
on the support of leaders to own and drive an organic, directed initiative with tasks and activities
applied to local specific organizational processes. The standardization of successful organic
processes can be found described in an early interpretation of a Deming management philosophy,
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known as Total Quality Management (TQM). Systematic standardization, top leadership
commitment and continuous improvement throughout the entire organization was at the heart of
the successful application of Deming management principles as applied to the Toyota Motor
Corp.35 However, it was noted that many laboratory leaders are taking the wait and see approach
to implementation of a standardized process that would embark on a framework in preparation for
QSR requirements.44
Contribution: In this paper, we continue the call for action for proactive leadership commitment
to prepare for regulatory requirements for laboratories that develop LDT. We propose the design
of a regulatory QMS framework, bridge the gap and illustrate expansion of the 12 QSE to include
the factors identified by a previous survey deemed to be optimal for a robust QMS.
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To avoid

duplication, we clarify, translate and integrate pertinent 21 CFR 820 design Control from the
medical device industry to the diagnostic laboratory framework.1 Finally, we illustrate and
propose expedited test development with the customization of an agile stage gate hybrid
methodology from product development to the laboratory.
Prior Research Findings
In our prior LDT publication, we reported results of a study to explore the concerns of the
laboratory community specific to the quality system regulations described in the 2014 draft
guidance.

44

The aim was to understand if compliance was possible, and if not, why and what

would be the limiting step. The interview responses obtained from laboratory professionals with
significant expertise in the field of LDTs expressed ambiguity regarding the FDA draft guidance
and questioned the meaning and adaptability of design control. In addition, they were unclear how
the requirement proposed by the FDA in the Quality System Regulation in general would translate
to the laboratory environment. The opinion of the professional interviewees expressed that
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laboratories offer a service, not a product and the QSR does not equate to the laboratory
environment.1 The 2015 FDA Workshop on Laboratory Developed Tests (Jan 8-9, 2015) also
included speakers offering direction and encouragement to the FDA to oversee the process of
LDTs for patient safety and offered advice for laboratories to begin to prepare.39
The authors explored the FDA regulatory requirements described in 21 CFR 820, defined
and clarified the terms and compared the directives to the 12 Quality System Essentials as
recommended by the CLSI. As we researched the translation of medical device requirements to
laboratories, we found commonalities in the manufacturing factors, however, we further identified
unaddressed gaps. As the result of qualitative interviews, literature searches and survey feedback,
eight strategic factors and 40 supporting statements were developed that addressed the gaps and
needs of laboratories. We tested the factors using a survey instrument for functionality, usefulness
and agility and all 35 participants agreed that the strategic factors were optimal for development
of a Quality Management System (QMS) regulatory framework. The survey respondents agreed
with the importance of leadership commitment for LDT, however, the results of the interviewees
yielded leaders that are taking the wait and see approach as opposed to being proactive.
What is a Quality Management System?
A Quality Management System (QMS) is “an integrated framework through which
organizations systematically define quality objectives linked to their broader strategic goals and
develop and implement foundations, organizational structures and processes to achieve these
objectives.” 45
The primary and most important step in the design of an integrated framework for QMS is
the need for a clear understanding of the terms and definitions of regulatory requirements pertinent
to the operation. In addition, Luzack (2012) describes the most important factor to be leadership
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commitment to dedicate the time and resources necessary to develop the documents within the
QMS that will direct and control all other activities.46 A significant benefit of a QMS is the
adherence to the strategic goals by horizontal control and shared roles across the entire
organization responsible for quality. As stated by Meeker et al. (2015), an integrated and flexible
QMS framework would proactively and strategically prevent and/or reduce risks in quality; a
significant benefit for the patient. 45
Material and Methods
Designing a Quality Management System
The design of a Quality System Regulation (QSR) or a Quality Management System
(QMS) is proposed based on six steps as depicted in Table 12. and are further described below
(note that terms QSR and QMS are used interchangeably in this text).
Table 12: Steps to Create a Quality Management System
Step Method
1

Understand the requirements

2

Cross reference the existing 12 Quality System Essentials to match the common 21
CFR 820 clauses

3

Perform an initial assessment to determine current laboratory policies, procedures and
processes

4

Develop and implement policies, procedures, processes that describe direction for each
requirement

5

Implement tasks associated with stage gate, agile hybrid methodology and assign a
responsible person(s) to perform a formal go/no go decision at each handoff of design
controls
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6

Develop a Quality Management System framework to include all the above

Step 1: Understand the Requirements
The initial step to developing a regulatory QMS is to understand the regulatory
requirements as they relate to the context of a particular organization. In addition, mission and
vision statements will provide insight regarding the nature of operations—forensic, high
complexity, high risk/ low risk, rare diseases, and LDT types.
Step 2: Cross Reference the QSE to the QSR
The elements covered by the 12 QSE and the clauses in the QSR are listed in Table 13.
The QSE contain most of the broad management categories included in the 21 CFR 820. The
majority of the 12 QSE’s should already exist in some form in many laboratories; however, the
extent of laboratory application may differ.

24

For each QSE depicted in Table 13, identify the

QSR on the right that most closely adheres to the activities in that QSE management principle.
Identify any outliers or unaddressed clauses. For example:
1. (QSE) Organization: (management oversight) = (CFR) Management Responsibility
2.

(QSE)

Occurrence

Management

=

(CFR)

Nonconforming

product

+

Corrective/Preventive Actions
To further clarify requirements, Table 14. depicts a cross reference of QSEs and QSRs and lists
many of the common activities associated with requirements for laboratory accreditation.
Table 13: The 12 QSE and 21 CFR 820 requirements
12 Quality System Essentials (QSE) CFR 820 Quality System Regulation (QSR)
Organization

Management Responsibility

Personnel

Quality Audit
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Equipment

Personnel

Purchasing and Inventory

Design Controls

Process Control

Document Controls

Document and Records

Purchasing Controls

Information Management

Identification and Traceability

Occurrence Management

Production and Process Controls

Assessments

Acceptance Activities

Process Improvement

Nonconforming Product

Facilities and Safety

Corrective and Preventive Actions

Service and Satisfaction

Labeling and Packaging controls
Handling, Storage, Distribution and
Installation
Records
Servicing

Step 3: Perform the Initial Assessment
The next step is an initial laboratory assessment to help laboratory leaders identify areas
that may lack adherence to regulatory requirements. This assessment will compare current
laboratory processes and guidance documents to QSE and CFR requirements. In the CFR, required
documents are denoted by the word shall in the clause. Existing documents should align to those
required by the QSE and QSR. The initial assessment includes, but is not limited to the descriptions
in Table 14.
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Table 14: QSE and QSR requirements 24,41
Quality System

CLSI QMS-01

Requirements

Quality System

(QSR)

Essentials (QSE)

Activities for Compliance

Subpart B, Quality

Management

Quality policy

Quality planning

System

responsibility

Organization

Quality system

Management review

procedures

Subpart C, Design

Classification rules

Design verification

Controls

Design and

Design validation

Requirements
(CFR)
Quality audits
Personnel

development planning
Design controls

Subpart D,
Document Controls

Design input

Design transfer

Design output

Design changes

Design review

Design history

Document approval
Document controls

and distribution
Document changes

Subpart E,

Evaluation of

Purchasing

Purchasing

suppliers, contractors,

Controls

controls

and
consultants
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Purchasing data
Subpart F,

Identification

Identification and
Traceability
Traceability
Subpart G,

Overall requirements

Buildings

Production and

Production and process

Equipment

Process Controls

change
Environmental controls Manufacturing material
Production and

Personnel

process controls

Contamination control

Automated processes

Control of inspection,
measuring, and test
equipment
Calibration
Validation

Procedures for

requirements Review

monitoring validated

effect of process

processes

Process validation

changes and revalidate

Subpart H,

Receiving, in-

General requirements

Acceptance

process, and

Activities

finished device

Receiving acceptance

acceptance

activities

Final acceptance
activities
Acceptance records
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In-process acceptance
activities
Acceptance status
Subpart I,

Control of

Nonconforming

nonconforming
Nonconforming

Product

product
product
Nonconforming review
and disposition

Subpart J,

Procedures for

Corrective and

corrective and
Corrective and

Preventive Action

preventive action
preventive action
Activities and results
must be documented

Subpart K,
Labeling and

Device Labeling

Packaging Control

Label integrity

Labeling operations

Labeling inspection

Control number

Labeling storage
Device Packaging

Subpart L,

Handling

Handling, Storage,

Procedures for control

Distribution, and

of storage areas and

Installation

Storage

stock rooms
Procedures that
describe methods that
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receipt from and
dispatch to storage and
stock areas
Procedures for control
and distribution of
Distribution
finished devices
Distribution records
Installation and
inspection instructions
Insure proper
Installation
installation, and
document inspection
and test results
Subpart M, Records

Confidentiality
Record retention
period
General

Exceptions - what

requirements

records do not need to
be provided to FDA
and what can be
presented instead

Device master
record

Device specifications

Packaging and labeling
specifications
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Production process

Installation,

specifications

maintenance, and
service procedures

Quality assurance
procedures and
specifications
Dates of manufacture

Primary identification
label(s)

Quantity manufactured

Any device

Device history
identification(s) and
record
control number(s) used
Quantity released
Acceptance records
Have procedures for
Quality system
and maintain complaint
record
files
Review and evaluate

Maintain records of

all complaints

investigations

Investigation of

Records of

complaints relating to

investigations must be

Complaint files

device failure, labeling, reasonably accessible to
or packaging

the manufacturing
establishment
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Review, evaluation,

If complaint unit is

and investigation of

outside of US, records

reportable events

must be accessible with
the US

Subpart N,

Where servicing is a

Any service report that

Servicing

requirement,

represents a reportable

procedures are required event shall be
considered a complaint
Servicing
and processed
accordingly
Analyze service reports Structure of service
report
Subpart O,

Where appropriate,
Statistical

Statistical

procedures for valid
techniques

Techniques

statistical techniques
Sampling plans, if
used, based on valid
statistical rationale

Appendix D. contains an assessment checklist that can be used to document existing laboratory
processes in comparison to the elements of the standard that may need to be addressed.
Laboratories may not perform all manufacturing processes described within each specific
requirement listed in 21 CFR 820. The following exception found in Subpart A, General Provisions
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Scope provides justification as follows: “if a manufacturer engages in only some operations subject
to the requirements in this part, and not in others, the manufacturer need only comply with those
requirements applicable to the operations in which it is engages”. 41 Note: the exclusion of activities
associated with clauses in the 21 CFR 820 requires rationale to omit and documentation recorded
in the quality manual. In addition to the operational requirements listed above, the elements
addressing design, manufacture, testing and approval of LDTs have historically not been included
in the original 12 QSE.
The requirements identified in Table 13 and the results of the initial assessment
documented on the assessment form in Appendix D. will provide insight into the elements needed
to craft a comprehensive quality framework. The final framework, integrated with QSE and the
QSR, is depicted in Figure 6.
12 Quality System
Essentials (QSE)
•Organization
•Customer Service
•Facilities and Safety
•Personnel
•Purchasing &
Inventory
•Documents &
Records
•Information
Management
•Nonconforming
Events
•Assessments
Continounal
Improvement

21 CFR 820 Quality
System Regulation
(QSR)

•Adoption of all CFR
requirements
applicable to the
laboratory not
previously included in
the 12 QSEs

Design Control

•Design &
Development
•Design input
•Design output
•Design Review
•Design Verification
•Design Validation
•Design Transfer
•Design Changes
•Design History

Figure 6: The 12 QSE integrated with 21 CFR 820 requirements
Step 4: Develop and Implement Policies, Procedures, Processes Identified as Missing During
Assessment

61
The process of cross referencing the 12 QSE to the 21 CFR 820 clauses and the results of
the assessment will provide an accurate determination of policies, procedures and processes still
required to develop a robust QSR. To comply with regulatory requirements, Table 13. represents
a high-level guide for the description of activities that must be addressed. For a more
comprehensive listing see the 21 CFR 820 Standard.41 Any existing documents not meeting
requirements should be revised and approved using organizational document management
protocols.
Step 5: Design Control
The fifth step includes design of a structure to include all elements of design control not
previously included in the 12 QSE. The prior assessment step will determine existing laboratory
processes that may align with elements of design control. Figure.7 lists each element of Design
Control and includes a high-level description for the development of pertinent laboratory guidance
documents. The laboratory shall develop of policies, procedures and processes as applied to test
design to ensure requirements specific to the laboratory are met and proper documentation is
maintained. Consistent documentation of all tasks and activities throughout each stage of
development is critical and will capture all changes and modifications as discussed in Design
history.
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• Establish a plan for testing
design,responsibilities,
specifications,paremeters,
outputs, validation and
verification methods.
• Review/documentation is
required

• The design reguirements
addresses the intended use
of the test and needs of the
user. Procedure for
discrepancies or conflicting
requirements in testing
required
• Review/documentation is
required

Design &
Development
• The design output
requirements
coorelate with the
design input
requirements and
is Reviewed and
documented

Design
Verification

• Design acceptance testing
is appropriate for the
results and the output
evaluates conformance to
results and intent of the the
tests
• Review/documentation is
required

Design Input
• The test conform to
the intended use
• Documentation of
method/results/
performance

• Test design translates to
live testing environment
and oucomes are as
intended
• Reviewed and
documented

Design
Validation

Design
Transfer

• Formal reviews conducted
throughout all stages of test
development
• Review/documentation is
required

Design
Review

Design
Output

• Plans are reviewed, verified,
validated and documented
throughout all testing phases
of development
• Reviewed and documented

Design
Changes

• Design a tracibility matrix
to show documenatation
linkages, documentation
between steps
• Reviewed and
documented

Design
History

Figure 7: Elements of Design Control for LDTs (21CFR 820) 29
Step 6: Establishing an Agile Stage Gate Methodology
To expedite the development of LDTs and ensure all steps are well reviewed and
documented, the framework may be further established by the use of a product development
methodology called Agile Stage Gate Hybrid. The agile methodology was initially established for
the speedy development of new software codes by IT leaders and currently are used in other
industries with high risk, proliferation costs and limited life cycles such as high tech and product
development. An Agile product development methodology differs from traditional (PD) due to
just-in-time internal/external communication and feedback to document and expedite change. The
traditional Stage Gate technique as described by Cooper (2008) consist of an initiative or project
(e.g., new product development, software development, process improvement, business change)
divided into distinct stages or phases, separated by decision points (known as gates). 47 The Stage
Gate process is described as a macroplanning process that begins with the discovery stage or an
initial deep understanding of requirements, explained as “camping with the customer”.47 An initial
planning meeting is held to define regulations, requirements, ideas, and develop the plan with
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strategic goals and productive outcomes. A manager is assigned at discovery to validate and move
the test through each gate to the next stage in development. The project then moves through the
process of scoping, building a business case, project development, testing, validation and launch
with a go or no-go decision at each handoff.
An LDT Launch Executed with Stage Gate Technique
Comparable to typical product development, the LDT process launch begins with the test
concept, design and development and the test is classified (Figure 8). Within Stage 2, the design
input addresses and verifies the intended use of the test and in Stage 3 clinical validity and the
conformance of the acceptance criteria is confirmed.

The task of Stage 4 is to verify that the

output of the design requirements meet the input criteria and Stage 5 serves to validate the process
under defined operating conditions. Stage 6 is the successful transfer of the test design to the live
laboratory environment; however, each stage does not advance until the go/no go determination is
made. The stage gate responsibilities include the following tasks: 1) Inspection at each phase and
2) Design change, review and history file to document all changes to the process.
A comprehensive review is conducted at post launch to discuss lessons learned and to identify
potential challenges for the next launch. This approach to an LDT launch will perpetuate clearly
communicated processing information, will expedite the process and allow for just-in-time
response and resolution to meet rapidly changing needs. This technique is credited with increased
team communication, positive outcomes, just-in-time responsiveness to rapidly changing customer
requirements and faster product to market.16
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Stage Gate step includes the following:
1. Inspection at each step
2. Design change
3. Design history
4. Design review

Figure 8: Agile Stage Gate Hybrid Technique adaptable to LDT development 49
The Application of Agile to Stage Gate
The agile function within the stage gate technique is considered a microplanning process
that utilizes a project management (PM) approach within each gate with specific activities and the
assignment of dedicated cross-functional teams. Cooper and Sommers (2016) describe that the
most successful applications of agile stage gate hybrid methodology come from organizations that
assign owners to each gate with the authority to stop the process due to quality concerns.48 The
dedicated teams manage, maintain and own the launch and are responsible to document details and
obtain approvals at each gate. In addition, the teams conduct short daily meetings usually 15
minutes in length to accomplish the following: 1) review accomplishments from the prior day, 2)
brainstorm resolutions to preexisting discrepancies, 3) prepare for the current day, and 4) review
team progress from past assignments.
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The technique is further divided using “sprints” (short iterations) to develop the project in
short increments or stages usually from one to four weeks. There are three types of agile stage gate
hybrid techniques:
1) Agile and Iterative Development: This type of application is effective when the process is
consumed with uncertainty, change and speed is crucial to success of the project.
2) Adaptive or Spiral: This technique employs multiple projects with extended iterations
when the process is continuously evolving.
3) Accelerated: This technique is optimal when speed is imperative by adapting the following:
1) Application of Lean tools such as value stream mapping to identify processes fraught
with waste and inefficiency and 2) Simultaneous execution to allow multiple projects to
intersect and advance without the need to remain in one stage until all information has been
established.48
Regardless of the agile technique employed, the process requires leadership to direct and own
the project with the immediate focus on the backlog of issues. The process is iterative and may
include cyclical projects simultaneously conducted at each step throughout the entire stage gate
(Figure.9). The team evaluates user needs by brainstorming new solutions and aligns the process
to accomplish positive outcomes. The new solutions are discussed at the daily or weekly sprint
meetings and a review is performed to understand lessons learned, successes, failures, assignments
and what’s next. The cyclical process continues.
The characteristics of the agile technique for LDT development include:
▪

Early and continuous customer (FDA) involvement

▪

An initial comprehensive planning meeting that includes all members of the team
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▪

Training for leaders and team members in the agile stage gate methodology prior to
execution

▪

Empowerment of teams and assignment of responsibility and accountability

▪

Establishment of the Rules of use: 1) Just in time communication requirements, 2)
Discussion of progress/failures, and 3) Consistent documentation at every step.

▪

Continuous learning

▪

Documentation and follow up of quality issues associated with the LDT process
Daily Review

Leadership vision and
support

Backlog

Evaluation of

Sprint

User needs
New solution

Test Concept

Design Input

Design Output

Design Verification

Design Validation

Design Transfer

Post launch
review

Figure 9: Agile methodology adapted to LDT development 49

Medical Test Validity
The CLIA regulations require laboratories to establish performance characteristics to
validate the accuracy and precision prior to testing patient samples. (42 CFR 493.1253). 50 Clinical
and analytical validity should be verified at each step. (Table 15.)
Table 15: Criteria for Medical Tests
Analytical

“Analytical validity defines the ability of a genetic test to measure accurately

Validity

and reliably the genotype of interest during pre-analytic, analytic and post-
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analytic phases of testing. This part of the evaluation is concerned with assessing
test performance in the laboratory as opposed to the clinic”. 51
Does the test measure what we say it measures?
Clinical

“Accuracy with which a test can predict the presence or absence of the phenotype

Validity

or clinical disease”. 51
Does the measurement correlate with a clinical situation?

To ensure the clinical validity of a test protocol the following activities and reviews may be
performed. 17
1. Linearity Study
2. Analytical Sensitivity
3. Precision
4. Analytical Specificity
5. Accuracy Comparison of Methods
6. Reference Intervals/cut off points
For more information regarding Clinical Validity, see CLIA regulations website.
Design History
In the stage gate technique, the team lead or process owner is responsible to follow through,
resolve issues and document tasks and activities interacted throughout the entire LDT process.
The illustrative example matrix depicted in Figure.10 can be used as a management tool to
maintain documentation. 29
NOTE:
Link each entry to file with additional information and data.
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Design History File Traceability Matrix
Design History File Traceability Matrix
Reviewed by/Date

Design Inputs

Reviewed by/Date

Design Verification

Reviewed
by/Date

Design Validation

Reviewed by/Date

Entry #

Date

User Needs/Regulation

1

1/12/16

Secured Supplier.
Performed Supplier
Qualification. Ok to use

RD

1/18/16

New supplier added to list

RD

Performed supplier performance
1/18/16 and monitoring. Supplier continues
to be accepted.

RD

1/26/16

DC

1/18/16

2

8/16/16

Testing- allergy Ag

RD

1/16/16

Ordered XYZ Reagent. Manufacture
insert stated dilution is stable for 8
hours

RD

1/16/16

Testing/QC check performed on
XYZ reagent on 8/14/16. OK to use.

RD

1/18/16

RD

1/20/16

3
4

1/12/16
8/16/16

MDR
Validation

RD
RD

1/18/16
1/16/16

Reportable error
(IP, OP, QP)

RD
RD

1/18/16
1/16/16

RD
RD

1/26/16
1/18/16

DC
RD

1/18/16
1/20/16

Figure 10: A matrix example of required documentation for LDT Design History
Step Process

Task

Documentation

1

Develop a policy, procedure and

All documents are controlled,

process for each QSE not already

readily available and the current

addressed

version

Develop a policy, procedure and

All documents are controlled,

process for each clause not

readily available and the current

included in the QSE

version

2

3

QSE

21 CFR 820

Risk

High risk: an incorrect result could to lead to serious consequences for

Classification

the patient. The application for premarket review must be submitted
prior to offering the test.
Moderate risk: an incorrect result may lead to the morbidity, mortality
or may compromise the safety of patients. The laboratory must submit
validation studies describing accuracy and clinical validity prior to
offering the tests for premarket review.
Low risk: an incorrect result or incorrect interpretation is unlikely to
affect morbidity, mortality or safety of patients.
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4

Design

Develop a policy, procedure and

All documents are controlled,

Control

process for each clause included in

readily available and the current

the QSR, Design Control

version

Step 6: Develop the Quality System
The development of a comprehensive and robust quality management system begins with
the adoption of the 12 QSE (Step 1) as explained in Table 16.

As stated previously, many

laboratories are adopting quality management standards, which (if executed to completion) will
prepare the organization for complying with regulatory requirements. Step 2 addresses the
establishment of guidance documents for the clauses within the 21 CFR 820 regulatory
requirements not already included in the 12 QSE. Step 3 describes the process for classifying LDT
risk--high, moderate or low risk. Regardless of the risk classification, the support structure of the
quality management system remains stable. Listed in Step 4 is the development of policies
processes, and procedures specific to each element of design controls.

When executed

appropriately these documents will allow for a cascade of verification steps from LDT initiation
to testing. The series of controlled hand offs will ensure a fail-safe process with quality built into
every step. Figure. 11 depicts the Stage Gate process that incorporates all elements of the QSR.
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Table 16: Steps to Develop a QMS
Organization

Personnel

Purchasing
& Inventory

Equipment

Process
Controls

Documents &
Records

Information
Management

Occurrence
Management

Process
Improvement

Assessment

Service &
Satisfaction

Facilities
& Safety

12 QSEs

Risk Classification

High Risk

Moderate
Risk

Rare Risk

Agile Stage Gate Hybrid
Gate
1

Stage 1
Test Concept
Design and
Development

Gate
2

Gate
3

Stage 2

Stage 3

Stage 4

Design Input
Test Classification

Design Output

Design Verification

High risk
Moderate risk
Rare risk

Analytic/Clinical
Validity

Gate
5

Gate
4

Stage 5
Design Validation

Stage 6
Design Transfer

Post
Launch
Review

Figure 11: Design of an Agile Stage Gate Hybrid Regulatory Quality Management System
Conclusion
The patient safety concerns identified by the FDA was a turning point in the history of
laboratories. Whether one is in support of the FDA draft guidance for a QSR in the laboratory, or
against it, we can all agree that a robust quality management system will provide the structure for
accuracy and efficacy of LDT design, development and testing, therefore, assuring patient safety.
The primary constraint of laboratories is the unfamiliarity of the regulatory standard, the meaning
of design control and the application to laboratory medicine. The challenge becomes the adoption
of an unfamiliar regulatory requirement and adoption of a formal design control methodology.
However, after careful review of existing processes the reader may identify some form of the
requirement already in place, but possibly named differently. The existing process can be
expanded to incorporate the requirement and the terminology is irrelevant if the guidance
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document and process address the regulatory requirement. Documentation of each regulatory task
and activity along the path of LDT is key to demonstrate compliance.
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CHAPTER 5. IMPLEMENTING AN AGILE QUALITY MANAGEMENT SYSTEM FOR
DEVELOPMENT OF LABORATORY DEVELOPED TESTS
“An accepted framework throughout our industry will set a level playing field as well as provide
structure, uniformity and integrity to the entire LDT process. ‘” (survey participant)
Overview
This chapter assists leaders develop a regulatory QMS structure that is comprised of six stages of
development. The six stages are as follows: 1) establishment of a leadership support structure, 2)
training, 3) pre-assessment of current laboratory processes, 4) adoption of design control, 5)
process controls, 6) process validation and the application of an agile Stage Gate technique for test
development.
Introduction
In 2014, the FDA released a draft guidance for laboratories that develop in-house tests
entitled Framework for Regulatory Oversight of Laboratory Developed Tests (LDT). 2 In this draft,
the FDA provides guidance for laboratories that manufacture LDT and explains that enforcement
discretion once considered optimal for laboratories is no longer appropriate due to the expansion
of LDT development. The agency acknowledges the current regulatory gap between CLIA and the
FDA. Joshua Sharfstein MD, (2015) asserts that these gaps in the present “regulatory system under
CLIA present a public health risk” and, in response, proposes risk classification, timeframes for
LDT registration, medical device reporting and a phased approach for implementation of a Quality
System Regulation (QSR) for laboratories that register LDT for Pre -Market Approval (PMA) or
510(K) classifications. 3
Due to differences of opinion within the pathology community, the FDA announced in a
Discussion Paper dated January 13, 2017 that a final draft guidance would not be issued to allow
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for additional public discussion and a legislative solution. However, the agency continues to
support the proposition for regulatory requirements from the 2014 draft guidance and, in a 2017
Discussion Paper 6, underscores the importance of a (QSR) for the development of LDT that
includes design controls, acceptance criteria and corrective and preventive action procedures.
In our initial publication, Facing the Inevitable: Being Prepared for Regulatory
Requirements for Laboratory Developed Tests, we discuss the prospect of FDA oversight within
laboratories. 44 We explore adherence to a QSR as proposed by the FDA, because we believe, as
does Gatter, (2017) that “it is unlikely that the issue is over”. 44,42 We also examine the potential
implications in the event the FDA gains greater authority over laboratories that develop in house
laboratory developed tests. Our goal is to understand the regulatory requirements and to consider
the adoptability of the proposal by laboratories, but more importantly to assess the understanding
of the community regarding these requirements. The original question that set the path forward for
this research was the following: Is compliance to the draft guidance possible, and if not, why not
and what are the constraints? 44
To gain an understanding and to answer this question, we interviewed nine laboratory
senior leader professionals with significant knowledge in the field of LDTs. 44
Their response yielded a significant lack of clarity regarding the FDA draft guidance and
substantial disparity regarding the meaning of design control as described in 21 CFR 820. In
addition, we found these leaders struggling to understand how design control could be adapted to
the diagnostic laboratory since the 21 CFR 820 uses terms relevant to medical devices, not
laboratories. 1 For the respondents, the intent of the FDA proposal is not fully delineated. The most
problematic finding from the responses was that the interviewees consider laboratory testing and
reporting a “service, not a product” and, by extension, not subject to “design control” regulations.
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Based on the interview results and literature searches, we developed eight strategic factors
and 40 supporting statements. 44 The strategic factors were tested for functionality, usefulness and
agility through a survey instrument. We found 35 survey participants in the field of LDT who
agreed with the eight strategic factors relevant for development of a Quality Management System
(QMS) regulatory framework.

44

In addition, we collected the top ten supporting statements and

associated strategic factors from participants considered experts in the field of LDT and developed
our findings into building blocks for a regulatory quality management system specific to
laboratories. The collection of this data serves to 1) clarify the needs of laboratories and 2) translate
the needs into laboratory terms and operational processes otherwise interpreted by the laboratory
community as applying only to medical device requirements. During the interviews for this initial
publication, we observed that leaders are taking a wait-and-see approach as opposed to a proactive
stance, while advice for laboratories from speakers that attended the 2015 FDA Workshop on
Laboratory Developed Tests Jan 8-9, 2015 is that “laboratories must begin to prepare.” 39, 44
In a sequel publication, Designing a Quality Management System for Laboratory Developed Tests
we propose translating the above eight strategic factors and 40 statements into a QMS design for
LDT oversight that would satisfy the QSR requirements applicable to laboratories. 52 We discuss
the comparison between the 12 Quality System Essentials as recommended by the Clinical
Laboratory Standards Institute (CLSI)

9

used by many laboratories to the 21 CFR 820

requirements. We demonstrate a process to identify and resolve noted gaps between existing
processes and requirements described in the QSR applicable to addressing LDT development in
the diagnostic laboratory. 52
Finally, in this second publication we explain the advantages of an agile stage-gate-hybrid
product development methodology successful in other industries as a novel approach to expedite
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LDT development. We illustrate the importance of dedicated cross-functional teams with the
authority to perform go/no-go approval/rejections at every step and the value in assigning change
agents and process owners. In conclusion, we suggest the design for a robust quality management
system framework that follows all pertinent regulations. 52
In this, our third paper, we illustrate the top ten supporting statements and associated factors chosen
from experts in the field of LDT, we highlight the findings from participant feedback and we
demonstrate the translation of those factors into an QMS implementation plan. This
implementation plan consists of operational processes, which can function as an extension of the
existing laboratory framework and can be crafted into a regulatory QMS for laboratories. We adopt
a proven product development methodology successful in other industries and customize it to a
novel approach for LDT development called Agile Stage Gate Hybrid technique. 47
The contribution to the literature: We provide the rationale to move away from the wait and see
approach regarding the adoption of regulatory requirements and we provide an implementation
guide for a regulatory QMS with structures that support LDT development. We include a novel
approach to LDT oversight by utilizing the Agile Stage Gate technique adapted to the laboratory
context which enlists dedicated cross -functional teams to manage and expedite LDT design and
development. We also suggest the assignment of change agents/process owners with the
accountability and authority to effect go/no-go approvals at every step. 48
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Figure 12: Elements of a quality management system
Prerequisite: A Quality Management System for Laboratories
A Quality Management System (QMS) is a diagnostic laboratory framework defined as
“coordinated activities to direct and control an organization with regard to quality”.

37

This

infrastructure, instituted in many laboratories, consists of the adoption of a set of management
standards called the 12 Quality System Essentials (QSE) as recommended by the Clinical
Laboratory Standards Institute (CLSI).

24

This systematic approach to quality considered by the

World Health Organization as a “path of workflow” begins with the patient and ends with the
diagnostic result; however, the depth of implementation varies across laboratories.

37

Consequently, a robust quality structure is only established through the comprehensive
development of policies, procedures and processes of each element designed at a local, organic
level. (Figure.12) The QMS elements are as follows: 53
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Goals of an QMS Implementation Guide
The goal of this research is to provide guidance for laboratories who wish to extend the
existing quality management system structure by adopting and incorporating pertinent QSR
clauses into their operational processes to demonstrate a proactive approach to LTD oversight and
to assure patient safety.
Materials and Methods
As stated earlier in this text, a QMS framework consists of a comprehensive collection of
policies, procedures and processes that address each management standard. In preparation for this
implementation guide, we assume that a comprehensive structure consisting of the 12 QSE (Table
17) has been previously implemented and is currently operational in the laboratory. The method
for implementing a regulatory QMS is outlined below:
1) description of the strategic factors and supporting statements identified as extremely important
for a QMS by experts for LDT development,
2) translation of pertinent interviewee/survey feedback into pertinent operational processes, and
3) implementation plan that describes the six phases of development, in sequential steps, and an
action item checklist.
Table 17: CLSI’s 12 Quality System Essentials Framework 24
1. Organization
2. Customer Service
3. Facilities and Safety
4. Personnel
5. Purchasing &Inventory
6. Equipment
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7. Process Management
8. Documents and Records
9. Information Management
10. Nonconforming Event Management
11. Assessments
12. Continual Improvement
Using the Strategic Factors as a QMS Development Guide
The top ten out of 40 strategic factors and supporting statements identified as extremely
important for a QMS by experts is used as a guide to design, develop, implement and extend the
existing laboratory framework to a regulatory QMS for LDT development. In addition, the
interview and survey participant feedback serve as rationale for the development of regulatory
processes within the implementation plan (all strategic factors and statements from the study are
listed in Appendix D. Table 18 lists the selected supporting statements paired with eight associated
strategic factors, interviewee feedback and the resulting implementation plan.
Table 18: Supporting statements with associated factors chosen by experts for LDT
development feedback and guidance contributing to implementation plan
Strategic

Supporting Statements

Supporting Feedback

Factors

Corresponding
Implementation
Plan Elements

1.Leadership

Statement 1: Leadership

Leadership provides “buy-

Top management

institutes key

in to review and re-

commitment,

performance indicators

evaluate whether current

strategic planning,

that outline, measure and

resources (both personnel
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direct regulatory

and equipment) are

employee

initiatives

sufficient to address QMS

empowerment

Statement 2: Leadership

gaps, maintain established

commitment to initiate

processes, implement

and maintain change in

change and allow the time

the organization

necessary for the

Statement 3: The

implementation of this

establishment of a QMS

work outside of normal

includes oversight by a

duties."44

knowledgeable, educated,
responsible, informed,
cohesive team to
effectively manage the
process
Statement 5: Leadership
consistently
communicates change
2. Training

Statement 7: The course

“Provide laboratories with

Understanding of

material includes

the tools to ensure LDT

regulatory

regulatory requirements

development is conducted

requirements, terms

and terms and definitions

and documented

and definitions

in alignment with CLIA

consistently, with the

88, 12 QSEs, 21 CFR

demonstration of
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820/QSR and Design

regulatory compliance as a

Control

by-product.” 44 (survey
participant)

3.*Pre-

Not on the list of most

"I do think that you could

Development of

assessment of

important

crosswalk each clause of

missing policies,

Part 820 to the elements of

processes,

each QSE and use the

procedures, job

QSEs as the QMS

aids, forms

framework for LDTs.

QSEQSR

current QMS

(survey participant)

4.*Design

Not on the list of most

“Design and document

Design and

Control

important

control is paramount for a

development: input,

5.Document

Statement 25: A

functional QMS.” 44

output, review,

Control

document control system

(survey participant). “

verification,

will ensure documents are

validation, transfer,

current and are readily

changes, history

available

files
Adverse event
reporting

6.Process

Statement 29: Clinical

“The biggest issue with

Clinical validity;

Control

validity is performed to

some of the most complex

performance

validate whether the

LDT's is the clinical

characteristics
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design and optimization

significance, and how

of the test protocol will

results derived from a

yield testing outcomes

LDT are being used or will

that can be used to

be used to guide therapy.”

develop a useful clinical

44

intervention.
7.Development

Statement 31: The

"A fully functional QMS

Agile Stage Gate

of a QMS

primary step to develop a

is needed for a laboratory

Hybrid technique to

regulatory QMS is to

to meet accreditation

expedite LDT

define a leadership

requirements.” 44

development

support structure with
defined roles,
responsibilities, and
oversight
8.Process

Statement 37: A

“Testing an ample number

Validation PQ, OQ,

validation

validation plan includes:

of samples to substantiate

PFQ

Process Qualification,

the intended outcome” 44

(PQ) Operational

(Interviewee # 3) Because,

Qualification (OQ), and

validation “is critical to

Performance

ensure the safety of the

Qualification (PFQ) to

patient and should be

verify that all steps in the

considered the standard of
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process meet or exceed

care. ”

regulatory requirements

2).

44

(Interviewee #

Statement 38: Process
Qualification (PQ)
ensures the necessary
components of the
process are implemented
according to design
specifications.
Documents necessary for
operation, performance
and maintenance are
verified and the process
includes all pertinent
factors

Note: The strategic factors 3) pre-assessment of the current QMS and 4) design control was not
considered extremely important but operationally necessary to identify processes that lack
adherence to standards.
Implementation Plan
The implementation plan includes the following:
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Phase I

Phase II

Leadership

Training

Top management
commitment,
Strategic planning,
employee
empowerment

Phase III
Pre- Assessment/
document
development

Understanding
of
regulatory
requirements,
terms
and definitions

Pre-assessment
analysis
Policies
Procedures
Job aids
Forms
Processes
QSE
QSR

Phase IV

Design Control

Design & Development
Design Input
Design Output
Design Review
Design Verification
Design Validation
Design Transfer
Design Changes
Design History Files

Phase V

Process Controls

Clinical validity

Phase VI

Process
Validation

Validation IQ,
OQ, PQ

Adverse Event
Reporting

Agile Stage Gate Technique for LDT Development

Figure 13: A QMS Implementation Plan consisting of six stages of development
Phase I: Development of the Leadership Support Structure
A leadership support structure provides the necessary resources to direct the initiative,
establish leadership oversight at each step throughout LDT development, remove obstacles within
the path of workflow, and provide ongoing support. Within this leadership structure, sponsorship
and directives are established, change agents are selected, team leaders are assigned, teams are
identified and meeting schedules are executed. The establishment of an expeditious pathway from
LDT development to FDA approval requires the commitment of leadership to own and direct the
initiative and dedicate the necessary resources to plan, develop, execute and communicate all tasks
and activities. John Kotter recommends the establishment of a dual operating system that consists
of traditional leadership to manage the organization and the recruitment of volunteer change agent
leaders through a “strategy accelerator network.” 54 This network employs volunteer change agents
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as leaders to dedicate sole responsibility for the initiative and assume the responsibility for
innovation, change, and strategic initiatives. 54
In this dual reporting structure, the change agent leadership commits to ensure a quality
structure that will sustain the initiative and provide ongoing support. In addition, will dedicate the
time to demonstrate accountability and ensure discrepancies within the flow of work are identified,
resolved, corrected and documented in real time. The dual reporting structure of leadership support
includes the following:
1. Traditional Leadership: Development of a regulatory strategic plan
a. Development of key performance indicators
2. Change Agent Leadership: Leadership participation, sponsorship and directives
a. Outline and measure compliance with regulatory initiatives
b. Participation and demonstrated support
c. Assignment of roles and responsibilities to every aspect of the QMS framework:
i.

The establishment of a QMS includes oversight by a knowledgeable,
educated, empowered, responsible, informed, cohesive team to effectively
manage the process.

3. Change Agent Leadership: Continuously communicates through the establishment of a
formal structure of change throughout the organization
Directions: Consider John Kotter’s dual reporting structure to assign a responsible, dedicated
change agent leader for LDT development: 54
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LEADERSHIP ACTION ITEMS: List the following:
1. Develop and communicate a strategic plan goal statement
a. Example: “The organization will develop and adopt a regulatory quality
management system within the next fiscal year.”
2. Provide leadership support for creating an LDT structure
3. Establish communication pathways to ensure continuous communication
throughout the process
a. Example:
4. Form an LDT Oversight Team
a. Leader
b. Team

Phase II: Training
The training includes understanding regulatory requirements, applicable terms, and definitions,
and the importance of documentation throughout the process. In addition, the training program
includes forming teams for each segment of the LDT process, assigning leaders and emphasizing
the importance of communication. Luzack, (2012) describes staff training as an essential
preparatory step in advance of implementation of a QMS because the key to effective
implementation is a knowledgeable team with an all-encompassing understanding of requirements.
46

The program outlined includes training modules for the following:
1. What’s My Role?
a. Introduction to LDT development, roles and the assignment of roles, responsibility
of leaders and staff “contributing to the success of the quality system”. 46
2. Understanding regulatory guidelines
a. Regulatory requirements and the understanding of terms and definitions for the
alignment of CLIA 88, 12 QSE, 21 CFR 820/QSR and Design Control
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3. Document Control to comply with Design Control
a. Document management is the operating control center of a QMS that provide
direction for staff to perform daily tasks and demonstrate objective evidence that
the LDT was performed according to policies and procedures.
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Training for

document control and record retention at a minimum should include the following:
i. New document development, review, approval and retention
ii. Review and approval of changes
iii. Documentation/review/approval/retention

at

every

step

of

LDT

development 53
4. Agile Stage Gate Hybrid Technique
a. The LDT process is clarified using standard project management tools, such as the
Stage Gate technique. 47 This process allows knowledgeable staff the flexibility to
expeditiously transport LDT successfully throughout the system, ensuring all
changes are well-reviewed, documented, and communicated in real time. The
training modules should include an understanding of the Agile Stage Gate Hybrid
technique that also include: accountability, ownership for go/no-go decisions at
each handoff, conducting short daily meetings or huddles and continuous followup to previous tasks.
Direction: Consider constructing the following for implementation of the training program:
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TRAINING ACTION ITEMS: List the following:
1. Identify subject matter experts to serve as trainers
2. Identify LDT team members who require training
3. List all pertinent organizational guidance documents, regulations and
specific requirements to be included in training
a. 21 CFR 820
4. Develop training modules
5. Schedule training

Phase III: Pre-Assessment and Development of Policies, Procedures and Processes
The pre-assessment phase includes a review of policies, processes, and procedures
within the existing management structure. This is a critical step commonly performed by
agencies for laboratory accreditation and ISO 15189 programs. The assessment performed
by these agencies help the laboratory outline the current state and future state of the QMS.
The adoption of ISO 15189 international standard for medical competence serves as a
system-wide approach to quality and provides guidance to develop, standardize and share
a common set of policies, processes, procedures and practices across the entire
organization.

45

Adoption of ISO 15189 will prepare the organization to reach a level of

quality more consistent with regulatory requirements. As stated earlier in this text,
significant variation exists between laboratories; however, laboratory accreditation is on
the rise in the US, resulting in higher laboratory quality. According to the College of
American Pathologists (CAP) there are 32 laboratories in the USA that have voluntarily
earned ISO 15189 accreditation and many pursuing additional quality management
standards.

13,38

Table 19. consists of reconfigured management requirements organized
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into similar clauses to demonstrate the commonality and alignment between 12 QSE, 21
CFR 820 and ISO 15189.
Table 19: QSE in comparison to the 21 CFR 820 requirements and ISO 15189 requirement
12 Quality System

21 CFR 820 Quality System

Essentials (QSE)

Regulation (QSR)

Organization

Management Responsibility

ISO 15189:2012

Management requirements
4.1 Organization and management
responsibility
4.2 Quality management system
4.15 Management Review

Personnel

Personnel

Equipment
Purchasing and Inventory

Purchasing Controls

Process Control

Acceptance Activities

4.6 External services and supplies

Production and Process
Controls
Document and Records

Document Controls Records

4.3 Document control
4.13 Control of records

Information Management
Occurrence Management

Nonconforming Product

4.8 Resolution of complaints

Corrective and Preventive

4.9 Identification and control of

Actions

nonconformities
4.10 Corrective action
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4.11 Preventive action
Assessments

Quality Audit

Process Improvement

4.14 Evaluation and audits
4.12 Continual improvement

Facilities and Safety
Service and Satisfaction

Servicing

4.4 Service agreements

Handling, Storage,
Distribution and Installation
4.7 Advisory services
4.5 Examination by referral
laboratories
Design Controls

Labeling and Packaging
controls
Identification and Traceability

Note: The activities described in some of the 21 CFR 820 clauses have no corresponding
clauses within other management standards and will require adjustment.
For a comprehensive description of all tasks and activities associated with each QSR see
the 21 CFR 820 standard at 21 CFR 820 Standard. 41
Implementation Step
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This phase requires assigned personnel to perform a review and to document alignment of
the management principles from the above standards to existing documents. This step requires the
review of all applicable requirements, organizational guidance documents and accreditation
general and technical checklists. The goal of this assessment is to develop a checklist of documents
that are incomplete or missing. (Table.20) The following is required to perform this step:
1. Personnel familiar and well versed in laboratory terms and definitions
2. All applicable guidance documents
3. Checklist
Table 20: Example checklist
Checklist

Exists Does Not
Exist

12 QSE are implemented in the laboratory
21 CFR 820 activities have been implemented
Design Control: Identify all activities that do not exist in the
laboratory
Other regulations

Direction: From the checklist, assign staff to develop the appropriate guidance documents in
compliance with all requirements.
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PRE-ASSESSMENT AND DOCUMENT CONTROL ACTION ITEMS: Confirm the
following:
1. Document all activities implemented to adhere to standard
Example
Process
1. Nonconforming Event

Alignment Confirmed
Policy
Procedure
X
X

Process
X

Training
X

1.
2.
Phase 3.
IV: Design Control Translated to Operational Terms
4.Design Control comparable to a product development methodology, was originally
5. for the medical device industry and was intended to manage the process of “designing
established
6.
purchasing,
manufacturing, packaging, labeling, storing, installing and servicing throughout the
entire product
lifecycle. 14 Design control applicable to the laboratory will require the development
7.
of organic
8. processes translated into policies, processes, procedures that capture all aspects of test
development with upstream and downstream links specific to each element of design control. The
potential exists for the laboratory to have established processes that already adhere to one or more
elements of design control. Design control applicable to the laboratory include documentation of
changes, review and approval at each step as described in a Design History file. See 21 CFR 820
QSR for each element of design control. (Appendix C.) 14
Table 21: Description of each element of design control with suggestions for procedures
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Step 21 CFR 820

Description

Design Control
1

2

Design and

Guidance regarding the plan, design, development, execution,

Development

involvement, interface with different groups and responsibility for

Planning

LDTs.

Design Input

Procedure that describes the intended use of the test, user needs and
the process to manage and resolve discrepancies. The process
includes responsibility approval, documentation and rationale at
each step.

3

Design Output

Procedure that describes the output of the design, provides rationale,
performance, specifications and criteria for verification that the
design successfully transferred into the testing environment.

4

Design Review

Procedure that describes how all phases of the design will be
reviewed with documentation and approval at each step.
Laboratories are required to establish and maintain procedures for
the identification, documentation, and validation, verification,
review, and approval of design changes before implementation.

5

Design

Procedure for determining that the test is safe, effective for use,

Verification

conforms to the needs of the user and meets its intended use.
Following the procedure ensures the design works as intended and
has been verified, documented and approved at each activity level.
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6

Design

Procedure to assure that validation is performed under defined

Validation

operating conditions to ensure the test is appropriate for the
intended use.

7

Design Transfer

Procedure to describe the accurate transfer of the design into
manufacturing requirements.

8

Design Changes

Procedure to identify, track, document and approve changes prior to
each change event.

9

Design History

A means to track processing information pertaining to design,
development, testing and links with all other design controls to
demonstrate traceability and approval for each LDT manufactured.

Direction: Review each pertinent element of design control as depicted in Figure 21 and
identify, develop and implement a guidance document for each topic.
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DESIGN CONTROL ACTION ITEMS: Directions
For each element of design control as depicted in Figure. 21, develop pertinent guidance
documents describing LDT activities specific to the processes performed in the lab.
Example:
Design Control
Design planning and
development
Design input
Design output
Design review
Design verification

Policy

Confirmed
Procedure

Process

Training

X

X

X

X

Design validation
Design transfer
Design changes
Design history
Design transfer

Phase V: Process Controls
Clinical Validity
Clinical validity defined as the “accuracy with which a test can predict the presence or
absence of the phenotype or clinical disease” 51 is currently limited to CLIA oversite for analytical
validation of tests. In addition, the FDA has proposed enforcement for clinical validation of tests
to include the establishment of the following: 50, 55
1. Accuracy
2. Precision
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3. Reportable ranges
4. Reference intervals
5. Interferences
For more information regarding Clinical Validity see CLIA regulations.
Directions: To ensure the clinical validity of a test protocol list the pertinent performance
characteristics and reference ranges for LDT:
PROCESS CONTROL ACTION ITEMS: Performance Characteristics
Performance Characteristics
Reference Range

Phase VI: Process Validation plan
To validate the effectiveness of the framework and ensure all tasks and activities meet the
regulation requirements, a validation protocol is developed to determine if the system is capable
of managing test variation with fluctuating volume in an agile environment characteristic of LDT.
A process validation protocol is utilized to ensure the LDT test development framework operates
as intended. 37
The validation plan includes: Process Qualification, (PQ) Operational Qualification (OQ), and
Performance Qualification (PFQ) to verify all steps in the process meet or exceed regulatory
requirements.
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Process Qualification: (PQ) ensures the necessary components of the process are implemented
according to design specifications. Documents necessary for operation, performance and
maintenance are identified and the process includes all pertinent factors.
Operational Qualification: (OQ) will ensure verification, documentation and that the process is
operating as intended.
Performance Qualification: (PFQ) demonstrates that the process consistently produces the same
result and operates correctly when used at defined capacities. Activities included in the PFQ will
test the entire system within the designed processes of the department, stress the system with a
documented the response, and ensure that quality checks on tests have been performed. This PFQ
stage of validation will test the overall process and ensure the system is performing as intended.
Figure.14 lists all factors suggested for review at each stage:
The validation items are as follows:
Process Qualification (PQ)
Item
Research Design approval
Employees are trained
Equipment maintenance
Polices developed/revised
Supplies planned in advance
Equipment validation
Design control guidance
Origin of an LDT
Proof of Concept
Protocol: Design & Development
Input & output design
Quality control documentation
Equipment validation
Training records
Testing equipment
Materials / reagents
Supplier Qualification
Regulatory guidelines

Operational Qualification (OQ)
Item
Test protocol is complete
Patient/Clinician involvement
Guidance documents
Supplier qualification/performance
Quality control
Standardized processes
Design transfer
Design changes
Design history file
Design validation
Equipment validation
Gaps - regulatory requirements
Gaps in the process
Supervisor oversight
Electronic tracking

Figure 14: Factors that comprise a validation protocol
Directions: Develop and implement the following:

Performance Qualification (PQ)
Item
Quality control checks
Reagent QC testing
Available supplies/reagents
Process owners
Discrepancies are noted/resolved
Document control
Employees are trained/competent
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PROCESS VALIDATION ACTION ITEMS: Validation Protocol
Confirm implementation of the following Completed:
Validation plan
Validation protocol
a.
Process Qualification
b.

Operational Qualification

c.

Performance Qualification

Validation Summary and Approval

Phase VII. Adoption of an Agile Stage Gate Hybrid Technique for LDT development
The Agile Stage Gate Hybrid technique is a combination of two common product
development methodologies that divide activities into stages separated by decision points. Each
decision point is a go (approval)/no-go (rejection) of each stage. 47 Agile was initially developed
to expedite software development; however, per Cooper, (2016) the combination of Agile with the
Stage Gate method of product development has yielded favorable advantages to industries outside
of software development and this technique has been shown to improve productivity and increase
speed. 48
The Agile Stage Gate Hybrid technique begins with strategic directives to plan and execute
the project as it moves through design, development, testing, validation and launch. An owner is
assigned to perform the tasks of go/no-go at each step and the process is further managed through
the assignment of a cross-functional team to document details, to manage the process and to initiate
a list of missing activities for each project that is rejected at the gate. The process may include
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multiple iterations of projects at each stage. To confirm that no project is delayed, a daily follow
up meeting is conducted to review current progress and to review prior commitments for each
phase which remain incomplete (backlog).

48

A designated team lead is assigned to manage,

perform and document a comprehensive review at each step and this information is discussed at
these brief daily meetings. The meetings capture progress, challenges and areas of improvement
which are then documented on white boards. By clearly communicating requirements, this
approach to a launch will expedite the process and will allow for just-in-time response, resolution
and documentation to meet rapidly changing needs. The goal of the meetings is to answer the
following questions:48
1. From voice of the customer - what does the internal/external customer value?
2. What are the deliverables that will address these values within the next phase?
3. What tasks are needed achieve the desired outcome?
A post LDT launch review is conducted to discuss lessons learned and to identify potential changes
for the next launch.
Applicable to LDT development, the process is reflective of design control beginning with test
concept and ending with a post launch review. Each phase includes a daily review, discussion of
the backlog, evaluation of user needs, a sprint (iteration) and back to the daily review as depicted
in Figure 15.
The responsibilities include the following:
1. Leadership oversite and responsibility for the progress of the project and for removing
barriers
2. Process owner to stop the process as needed
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3. Knowledgeable cross functional team as subject matter experts with process responsibility
and dedicated space to conduct daily meetings
4. Stage gate go/no-go position performs the following functions:
a. Inspection/review/documentation at each step
b. Design change/review/documentation
c. Design history/review/documentation
d. Design review/documentation

Figure 15: Agile Stage Gate Hybrid model for LDT development

Directions: Review and implement the list of items necessary for adoption of an Agile Stage
Hybrid technique for LDT development.
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Discussion
The LDT discussion began when we attempted to answer the question, “is compliance to
the draft guidance possible, and if not, why not and what are the constraints?”

44

To answer this

question, we conducted interviews with experts in the field of LDT. We proposed and tested factors
translated from their responses and concluded the suggested factors were optimal for development
of a regulatory QMS. Conversely, the understanding of regulatory requirements, translation of
those requirements (design control) to operational processes and the assurance of performance
through process validation were unclear.
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The lack of understanding by the laboratory community and the need for a regulatory QMS
was further supported by Liz Lison, president of Advocea Consulting firm (2015) and a 2015 FDA
Work Shop speaker that stated, “Most of the failures that I have seen in LDT may have been
averted if design controls had been in place.” 39
To assist laboratories, consider the adoption of design control, we provide a support
structure to define regulatory terms, recognize the current laboratory structure and implement
missing elements in comparison to the QSR. Moreover, we suggest a systematic approach to
implementation of design control through an agile stage gate technique for test development by
leadership oversite, assignment of owner accountability, teams, sprints and noted responsibility.
We illustrate a standardized, consistent pathway for LDT development by the delegation of a stage
gate coordinator tasked to perform design control reviews, changes and documentation of history
requirements at each stage gate.
This systematic approach to implementation of a regulatory QMS, will simplify the
translation of medical device requirements to the diagnostic laboratory.

Once considered

impracticable and unachievable is now promising through the attainment of knowledge, creativity
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and the enthusiasm for change. Mahatma Gandhi reminds us “we need not wait to see what others
do” but, to be the change we want to see in the world. That will require moving past the status
quo as seen in many laboratories today as this is the way we have always done things to how can
we improve the process that will ultimately ensure patient safety?
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CHAPTER 6: CONCLUSION & DIRECTIONS FOR FUTURE RESEARCH
Conclusion
The impetus for change within the laboratory environment began with the awareness of
patients adversely affected by outcomes associated with Laboratory Developed Tests.
Consequently, the design, development and manufacture of LDTs is not under the jurisdiction of
CLIA and testing operations is not formally within the oversight of the FDA.
The interviews with nine expert senior professional leaders within in the field of LDT
across regulatory, laboratory, accreditation and medical device industries served as the authority
based on their stature and established the consensus for the response of topics discussed. Many
interviewees claim the laboratories offer a “service, not a medical device” and furthermore, the
FDA has no jurisdiction over LDT. 1 However, before proposed legislation can occur the agencies
must bridge the gap between required regulations. Shelia Walcoff of Goldbug Strategies (2015)
and a FDA Work Shop speaker stated that “It is essential that FDA harmonize the QSR
requirements with CLIA requirements at a more granular level to prevent duplicate efforts and to
ease the regulatory burden” because governmental agencies have not provided the necessary
guidance for struggling laboratories.” 39
The interviewees shared this concern for CLIA and the FDA, however, before legislation
can occur the agencies must collectively develop standards and guidance documents prior to a
policy release because laboratories are misguided and unclear how FDA regulations translate to
the laboratory. The adoption of a quality system regulation to ensure accurate test development
appears incomprehensible under current laboratory operating structure. The lack of standards has
resulted in fluctuating levels of quality within laboratories and implementation of process
standardization and 12 Quality system essentials is based on the support of leaders to own and
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drive an organic, directed initiatives with tasks and activities applied to local specific
organizational processes.

53

A call for action has been initiated to promote proactive leadership

commitment to prepare laboratories for the inevitable.
Moreover, the current FDA regulations 21 CFR 820 are developed for medical device and
translation to operational laboratory terms does not exist. As a result, laboratories are taking the
wait and see approach and have not registered their tests with the FDA, meanwhile, the FDA
continues to understand the testing needs of the laboratories. The absence of test registration
creates the inability of the regulatory agencies to create a standard reporting structure; without a
standard reporting structure, laboratories continue to struggle to understand how these proposed
changes will affect current operations. Gatter, (2017) has stated “it is unlikely that the issue is over
“.42

In fact, in the January 13, 2017 discussion paper the FDA indicates support for CLIA

requirements regardless of the dissimilarity to 21 CFR 820 Quality System Regulation
requirements and continues to recommend a QSR “consistent with the approach described in the
discussion paper” for FDA requirements not mandated by CLIA. 6
In support of the FDA Discussion paper, the survey respondents agreed that a regulatory
oriented framework for the development of LDTs is needed in the laboratory.

This was

substantiated by results of exploratory research that included responses from 51 survey
respondents out of a population of 767 attendees at the Executive War College Laboratory
Conference in New Orleans, May 2016. Although the survey was sent to a large population of
conference attendees the population included leaders within all areas of the laboratory including:
sales, diagnostic imaging, medical device, diagnostic laboratories, reimbursement firms and many
others. Moreover, the field of LDT is a small niche market so the response rate of 51 survey
participants was a result of actual attendees that claimed to be experts in the field of LDT.
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It was interesting to note that the survey respondents as experts in the field of LDT did not consider
design control as extremely or very important despite the proposal for a QSR by the FDA. In
addition, the eight suggested strategic factors and 40 statements derived from the literature,
interviews and the FDA work shop provided the impetus for design of an QMS regulatory
framework.
The respondents agreed with all statements relevant to the design of a QMS based on needs
and gaps expressed by laboratory professionals. This finding aligns with the results of the survey
as there was no significant difference in the way the experts verse non- experts responded to factors
and associated statements. All respondents chose most statements as 1) extremely important or 2)
very important. This finding aligns with the recommendation by Katherine Tynan, an independent
regulatory consultant from the 2015 FDA workshop that offered advice to governmental agencies
as follows:
4. “Develop a common vocabulary that laboratories can understand”
5. “Simplified the cumbersome QSR and assist laboratories translate the directives”
6. “Develop a “QSR fit for purpose and harmonize the standard”
Katherine’s advice to laboratories was to “invest in a quality management system, implement all
factors of design control, and be proactive and prepare for future regulatory requirements.” 39
Consequently, the interviewees agreed that the terms, expectation and current recommendations
lack user definition, specific methods for testing protocols, and clear testing requirements. The
preparation of a QMS require the understanding where gaps exist to develop appropriate processes
that would to adhere to requirements, however, the survey statement suggesting review of current
policies and procedures to identify gaps was not considered important by all groups. This was an
interesting conclusion, since this is general practice within laboratory accreditation agencies.
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A process to incorporate the accreditation and regulatory standards has been customized
from product development to test development for the diagnostic laboratory. The agile stage gate
hybrid technique incorporates design control with the assignment of process owners, cross
functional teams, and a stage gate coordinator to perform review, changes and history tasks and
activities.
Resolution of Research Questions
The research question 1: Can laboratories operationalize a quality management framework
that will meet FDA requirements? The preparation of a QMS necessitates laboratory leadership
to understand the proposal by the FDA regarding all facets of LDT, take the initiative and provide
the appropriate resources to bridge the gap from an accreditation focused operating structure to a
regulatory framework. The survey participants concurred that the most favorable factors to design
and implement a regulatory QMS consist of tasks and activities associated with the following
categories: 1) Leadership, training, pre- assessment, 2) design control, 3) document control, 4)
process control, 5) development of a QMS framework and 6) process validation. The test
development process is then navigated through the agile stage gate hybrid technique to expedite
test development to satisfy the supply chain of service, process and people.
Research question number 2: Will an adoption of a quality system framework provide the
manufacturing foundation that will adhere to 21 CFR 820 Design Controls?
The manufacturing foundation built from the strategic factors discussed above is expanded
to include tasks and activities within each element of design control. This customized product
development methodology translated from medical device to the laboratory testing environment is
further expanded by utilization of the agile stage gate hybrid technique for LDT launch. The
technique is customized by the establishment of laboratory leads as owners that contain the
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authority to reject and stop the process due to quality concerns. In addition, the role of stage gate
coordinator was established as an objective position to perform review at each gate and document
changes and history throughout test development.
Directions for Future Research
The future research in the field of LDT can be pursued along four areas: 1) Live pilots for
the development of a regulatory QMS for in-house LDTs, 2) Product development methodology
adaptable to the laboratory, 3) Implication of venture capitalist funding/support for or against LDT
development, and 4) Enhancement of current regulations for the adoption, clarification and
registration of tests for risk assessment.
1) I plan to be involved with a pilot to be conducted in a live environment at the Department of
Defense in Washington DC. The goal of this pilot is to demonstrate and substantiate outcome
measures, lessons learned and the feasibility to move laboratories from the status quo to a system
designed for patient safety. This approach will require proactive leadership, resources, creativity
and innovation and may be considered the most significant step towards diffusion since
development of the Laboratory Improvement Amendment Act (CLIA) under the Centers for
Medicare and Medicaid Services (CMS) in 1967, 1988. 4 The live pilot in the laboratory will
investigate the need for “tailored” framework developed for the LDT community based on test
complexity, risk, and volume.
2) Another area for future research is the adoption of a product development methodology to the
laboratory environment to address risk management, test allocation, planning and implications of
limited resources across a portfolio management approach to LDT development with the
opportunity to explore share resources and components for similar tests access multiple
laboratories.
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3) Another line of extension for future research would be to investigate the influence of venture
capital (VC) funding for LDT development. While VC funds would be interested in quicker and
larger returns on investment (ROI), they would also be concerned about adverse health risk
events associated with the tests. It would be interesting to investigate whether this would require
any modifications to the proposed QMS framework.
4) Establishment of technical requirements associated with clinical validity, performance
characteristics or risk classification addressed in more detail by the CLIA under the Centers or
Medicare and Medicaid.
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APPENDIX A. E-MAIL INVITE FOR INTERVIEW
Good afternoon,
My name is Rita D'Angelo, the former Quality Manager from Henry Ford Health System,
Pathology and Laboratory Medicine in Detroit, Michigan.
I am currently working on my Ph.D. dissertation and I'm seeking an understanding and
clarification on the regulatory perspective of Laboratory Developed Tests.
Are you available for a 30-minute phone interview to answer a few questions regarding the position
of CAP accreditation/CLIA, FDA and the future implication for laboratories?
Thank you for your assistance and participation.
Warm regards,
Rita D’Angelo
PHD Candidate
Wayne State University
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APPENDIX B. INTERVIEW PROTOCOL- LABORATORY DEVELOPED TESTS
Date: ___________________
Interviewer initials:

Time frame of Interview:

Interviewee initials: Location:
Event #

Recording #

Introduction
Hello, my name is Rita D’Angelo and I am a student of Wayne State University working towards
my Ph.D. dissertation. I am conducting research to learn about the process of Laboratory
Developed Testing (LDT protocols within medical laboratories. I would like to understand more
about this topic from the perspective of governmental policy, challenges of Laboratory leadership
and potential process changes. I sincerely appreciate your assistance and making the time available
for me to ask you some questions.
The goal of this interview is to learn your perspective, understanding and outlook on Laboratory
Developed Tests as it relates to the overarching federal requirements and future strategy. I
encourage you to be as open and candid with me as possible and I pledge to keep your responses
confidential. I will interview many staff members that have a direct responsibility, oversight or
outcome associated with Laboratory Developed Tests. I am searching for strategy, future direction
and process related information across the interviews. I will compile findings and summarize the
results without identifying anyone specifically.
Do I have your permission to record this interview? This will allow me to time to document and
verify the accuracy of my notes. Recordings will not be shared with anyone and will be destroyed
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at the conclusion of our project. Please feel free at any time to ask me to stop the recorder if you
want to say something or alert me if you do not wish to be recorded. Can I proceed?
Feel free to ask any questions before we begin.
1. What is your role and responsibility in the organization?
a. What is your title?
2. Tell me about the history and your knowledge about of Lab developed Tests?
3. What are some of the regulatory challenges associated with LDT’s?
4. How does genetic testing influence regulatory oversight?
5. Describe the current scrutiny associated with regulatory guidelines for LDT’s?
6. What is the role of the FDA in lab developed tests?
7. Explain the intent of the FDA guidance framework for LDT’s released December 2014?
8. In your opinion, what would the implications(s) be if the FDA mandated regulatory
guidelines for the process of LDT’s?
9. How would you describe the “outcome and view of the future” if the FDA mandates
regulatory oversight for LDT’s?
Thank you for your time and attention. This is the conclusion of the interview. Please do not share
these questions with anyone.
If you think of anything else that you would like to share or if you know someone else that would
be beneficial in this process, feel free to contact me by e-mail or phone. All interactions,
information and conversations are maintained as confidential.
Thank you!
Follow-up-Name:

Date of Follow-up;
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Next meeting-Name:

Date of Next Meeting:
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APPENDIX C. DESIGN CONTROL
General. (1) Each manufacturer of any class III or class II device, and the class I devices listed
in paragraph (a)(2) of this section, shall establish and maintain procedures to control the design
of the device in order to ensure that specified design requirements are met.
(b) Design and development planning. Each manufacturer shall establish and maintain plans
that describe or reference the design and development activities and define responsibility for
implementation. The plans shall identify and describe the interfaces with different groups or
activities that provide, or result in, input to the design and development process. The plans
shall be reviewed, updated, and approved as design and development evolves.
(c) Design input. Each manufacturer shall establish and maintain procedures to ensure that the
design requirements relating to a device are appropriate and address the intended use of the
device, including the needs of the user and patient. The procedures shall include a mechanism
for addressing incomplete, ambiguous, or conflicting requirements. The design input
requirements shall be documented and shall be reviewed and approved by a designated
individual(s). The approval, including the date and signature of the individual(s) approving the
requirements, shall be documented.
(d) Design output. Each manufacturer shall establish and maintain procedures for defining and
documenting design output in terms that allow an adequate evaluation of conformance to
design input requirements. Design output procedures shall contain or make reference to
acceptance criteria and shall ensure that those design outputs that are essential for the proper
functioning of the device are identified. Design output shall be documented, reviewed, and
approved before release. The approval, including the date and signature of the individual(s)
approving the output, shall be documented.
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(e) Design review. Each manufacturer shall establish and maintain procedures to ensure that
formal documented reviews of the design results are planned and conducted at appropriate
stages of the device's design development. The procedures shall ensure that participants at each
design review include representatives of all functions concerned with the design stage being
reviewed and an individual(s) who does not have direct responsibility for the design stage
being reviewed, as well as any specialists needed. The results of a design review, including
identification of the design, the date, and the individual(s) performing the review, shall be
documented in the design history file (the DHF). (f) Design verification. Each manufacturer
shall establish and maintain procedures for verifying the device design. Design verification
shall confirm that the design output meets the design input requirements. The results of the
design verification, including identification of the design, method(s), the date, and the
individual(s) performing the verification, shall be documented in the DHF.
(g) Design validation. Each manufacturer shall establish and maintain procedures for
validating the device design. Design validation shall be performed under defined operating
conditions on initial production units, lots, or batches, or their equivalents. Design validation
shall ensure that devices conform to defined user needs and intended uses and shall include
testing of production units under actual or simulated use conditions. Design validation shall
include software validation and risk analysis, where appropriate. The results of the design
validation, including identification of the design, method(s), the date, and the individual(s)
performing the validation, shall be documented in the DHF.
(h) Design transfer. Each manufacturer shall establish and maintain procedures to ensure that
the device design is correctly translated into production specifications.
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(i) Design changes. Each manufacturer shall establish and maintain procedures for the
identification, documentation, and validation or where appropriate verification, review, and
approval of design changes before their implementation. (j) Design history file. Each
manufacturer shall establish and maintain a DHF for each type of device. The DHF shall
contain or reference the records necessary to demonstrate that the design was developed in
accordance with the approved design plan and the requirements of this part.
Source: 21 CFR 820, Design Controls, FDA (2014)
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APPENDIX D. LABORATORY ASSESSEMENT WORKSHEET
Assessment Statement
Exists

Does
Exist

1. All 12 QSE are implemented in the laboratory
2. List missing QSE
3. QSE comply with QSR
4. Identify all outliers
5. All 21 CFR 820 activities have been implemented
6. Design Control: Identify all activities that do not exist in the
laboratory
7. All elements of design control have been implemented
8. There is documentation for research and development of test
design and service development.
9. Responsibility for design and development activities are
defined
10. Design input, review and output activities are defined.
11. Documentation exists for design and history of change.
12. There is documentation for design transfer to testing
parameters
13. Documentation exists for initiation of LDT
14. Logistics are in place to support the supply chain

Not
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15. A process in place to secure appropriate supplies and
reagents
16. There are procedures and processes for supplier qualification
17. There a process for supplier performance and monitoring
18. Design control elements are applied
19. There is validation plans for equipment and processes
20. Customer supplier interaction exists throughout the lifecycle
to resolve discrepancies and documentation maintained
21. Quality control performed for all testing and records are
maintained
22. A standard format exists for result reporting
23. Policies, procedures or processes
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APPENDIX E. QUALTRICS SURVEY RESULTS: MANAGEMENT CATEGORIES AND
40 STATEMENTS
Q1: Leadership
Statement 1: Leadership institutes key performance indicators that outline, measure and direct
regulatory initiatives
Statement 2: Leadership commitment to initiate and maintain change in the organization
Statement 3: The establishment of a QMS includes oversight by a knowledgeable, educated,
responsible, informed, cohesive team to effectively manage the process
Statement 4: Establishment of an LDT quality committee to quickly approve changes and provide
support
Statement 5: Leadership consistently communicates change
Q2: Training
Statement 6: The training program includes a basic introduction to the manufacture of LDTs and
the roles and responsibility of leaders and staff
Statement 7: The course material includes regulatory requirements and terms and definitions in
alignment with CLIA 88, 12 QSEs, 21 CFR 820/Q SR and Design Control
Statement 8: The program includes value stream mapping to demonstrate the significance of
hand- offs, tasks and activities and all aspects of the LDT process beginning with research and
development and ending with diagnostic testing
Statement 9: Staff training includes the process of successfully navigating the LDTs through the
system to ensure all changes are well reviewed, documented and communicated
Statement 10: The assignment of responsible persons(s) to address, resolve, communicate and
document testing concerns
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Q3: Pre- assessment
Statement 11: The review of existing laboratory processes in comparison to the list of 12 QSE
management principles will identify policies, procedures or processes not previously addressed
Statement 12: Quality management standards, such as ISO 15189 if executed to completion will
better prepare the organization to comply with regulatory requirements
Statement 13: A cross walk of current processes in comparison to 21 CFR 820 quality system
regulation will assist laboratory leaders identify and understand pertinent gaps in the QMS
Statement 14: A pre- assessment of existing policies, procedures and processes may reveal
informal processes or documents not previously considered compliance to a regulatory
requirement
Statement 15: A clear understanding the QSR requirements is key to implementing processes for
a robust quality management system
Q4: Design Control
Statement 16: Implementation of all aspects of design control including design, development,
input, output, review, verification, transfer, changes and history will demonstrate adherence to
regulatory requirements and patient safety
Statement 17: Design control described in laboratory terms will clarify the requirements for
translation and adaptability to the laboratory environment
Statement 18: Design control well implemented and documented will ensure quality is built into
every step
Statement 19: The translation of 21 CFR 820 requirements into laboratory terms will highlight
and address the content required for the development of standard operating procedures
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Statement 20: A procedure that address the process for identification, documentation and
reporting of an adverse event is referred to as medical device reporting
Q5: Document Control
Statement 21: Updated and accurate standard operating procedures serves as verification of
compliance
Statement 22: A clearly written procedure for each phase of test development will remove any
ambiguity in the process
Statement 23: Record retention and timely retrieval of documentation related to the design,
manufacture and testing of LDTs demonstrated regulatory compliance
Statement 24: Documentation of tasks and activities at each step of the test development process
is captured, reviewed and approved to address the design history requirement
Statement 25: A document control system will ensure documents are current and are readily
available
Q6: Process Control
Statement 26: The process of LDT manufacture include assigned tasks and responsibility at every
hand- off to ensure concerns are identified, resolved, documented and communicated
Statement 27: The consistent uninterrupted flow of material, product, and information between
handoffs is critical to demonstrate the user friendliness of the framework
Statement 28: Documentation of analytical validity will demonstrate and document the accuracy
and reliability of test performance
Statement 29: Clinical validity is performed to validate whether the design and optimization of
the test protocol will yield testing outcomes that can be used to develop a useful clinical
intervention
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Statement 30: Data collection and clearly communicating requirements in an LDT launch will
expedite the process and will allow for just-in-time response and resolution to meet rapidly
changing needs
Q7: Development of a QMS Framework
Statement 31: The primary step to develop a regulatory QMS is to define a leadership support
structure with defined roles, responsibilities and oversight
Statement 32: Employee training describes terms definitions and regulatory requirements for the
development, manufacture and testing of LDTs
Statement 33: Performance of a cross walk or pre- assessment to detect all aspects of the current
QMS in comparison to CLSI and QSR requirements
Statement 34: Review the pre- assessment findings and create a list of necessary guidance
documents in need of development
Statement 35: Develop missing policies, procedures and processes to comply with regulatory
requirements
Q8: Process Validation
Statement 36: Process validation is performed to ensure effectiveness of the framework
Statement

37:

A

validation

plan

includes

Process

Qualification(PQ),

Operational

Qualification(OP) and Performance Qualification(PFQ) to verify that all steps in the process meet
or exceed regulatory requirements
Statement 38: Process Qualification (PQ) ensures the necessary components of the process are
implemented according to design specifications. Documents necessary for operation, performance
and maintenance are verified and the process includes all pertinent factors.
Statement 39: Operational Qualification will ensure the process is operating as intended
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Statement 40: Performance qualification (PFQ) demonstrates the process consistently produces
the same result and operates correctly when used at defines capacities.
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APPENDIX F. INTERVIEW RESULTS
Interview Topic # 1: Risk Classification
The most critical ambiguity mentioned ten times within all nine interviewees was the inability to
identify testing categories into high, moderate or low classifications and the process of LDT
registration. There is no current LDT approval process in place and very “few laboratories have
registered their LDT with the FDA.” (Interviewee # 7) Because very few laboratories have taken
this proactive step no “precedent has been set” (Interviewee # 7) making the test approval process
daunting at best. Despite the lack of clarity by the FDA, New York State (NYS) has currently
mandated all laboratories that develop LDTs to register their tests and classify their risk as of
November 14, 2016.3
Interview Topic # 2: Validation of Test Systems
Another common theme among the participants was the accuracy of test development and
validation to ensure patient safety. Interviewees emphasized the importance of systems to validate
protocols, processes and test development that will consistently ensure the effectiveness and
accuracy of test results. All interviewees shared a common concern regarding the effectiveness of
test validation and future requirements to formally “test an ample number of samples to
substantiate the intended outcome” (Interviewee # 3).
Interview Topic # 3: Uncertainty Over Future LDT Mandates
There was significant trepidation expressed by all interviewees regarding the uncertain future of
FDA mandates over every aspect of the LDT process. The participants expressed concern and
ambiguity regarding the draft guidance and its consequences should it become final policy. For
example, if the FDA mandates clinical trials for the development of high-risk tests, as required for
medical devices, many smaller laboratories without adequate resources may find it necessary to
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outsource their LDTs, discontinue them, or partner with larger laboratories. This concern is
substantiated by Klein,( 2016) who states that significant financial consequences exist for
laboratories and that the proposal as written could cause discontinuance of many LDTs.12 Larger
laboratories, including reference laboratories, have a competitive edge over smaller labs, including
the utilization of advanced genetic testing technology like Next Generation sequencing. This
technology generates enormous amounts of disease-related data in real time, and in support of
LDT development and validation.
Interview Topic #4: Patient Safety Measures of Accuracy and Efficacy
Eight participants expressed concerns that the lack of regulatory oversight for LDTs may have led
to adverse patient safety outcomes such as the misdiagnosis of serious illness as a result of
inaccuracies of testing protocols and their results. Additionally, patients may have been treated
for disease they did not have, or did not receive treatment for diseases they did have. The common
sentiment expressed during these interviews was of the need for thoughtful consideration of the
accuracy of test development, safe-testing practices, test verification and reproducibility of results.
The interviewees described their concern for accurate testing outcomes and process validation.
One participant stated that process validation “is critical to ensure the safety of the patient and
should be considered the standard of care” (Interviewee # 2).
Interview Topic # 5: Adopting a Quality System Regulation Framework
Six participants discussed their concern for laboratories being able to adopt this framework and
raise the level of quality within their organizations. They shared a common response that
laboratories lacked the rigor that is required for the manufacture of medical devices, and that could
translate to LDT development. Change is necessary in order to raise the level of quality, prioritize
tasks and dedicate the time and resources necessary to understand regulatory requirements in order
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to attain process standardization. Ambiguity existed during the interviews regarding the definition
of design control and how to appropriately address these requirements. As reinforcement of this,
Liz Lison, president of Advocea Consulting firm and a conference speaker at the 2015 FDA
Workshop on Laboratory Developed Tests explained, “Most of the failures that I have seen in
LDTs may have been averted if design controls had been in place. Therefore, I urge the agency
not to delay the enforcement of design controls for high-risk tests and potentially introduce a two
-tier system for pre-market review”.13
Interview Topic # 6: Accreditation
Six participants stated that the FDA lacks the resources necessary to inspect all labs across the
USA and would eventually require the assistance from third party accreditation agencies. As stated
in their 2017 Discussion Paper, the FDA explains, “expansion of inspection will include a “third
party inspection program for LDTs so that many of these post-market inspections could be
conducted by FDA-accredited third parties. This would allow such third parties, when appropriate,
to inspect for the three additional FDA QS requirements at the time of a routine CLIA survey
inspection.”14 The FDA appears to be working towards this by exploring opportunities to
coordinate with and leverage existing programs such New York and other programs managed by
organizations approved by CLIA.14
Interview Topic #7: Quality Management System
Four interviewees indicated that in the absence of a policy and a defined set of standards,
laboratories will likely take the wait and see approach, not progressing with change or development
until required. Because “development of a quality structure takes a considerable amount of time”
(Interviewee #3), laboratories should consider whether to prepare in anticipation of regulatory
changes. In the face of uncertainty over how 21 CFR 820 requirements applies to laboratory testing
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services, laboratory leaders need greater clarity on understanding and preparing for a QSR
framework. Katherine Tynan, an independent regulatory consultant at the 2015 FDA Work shop
on Laboratory Developed Tests, expressed her concerns and offered advice to governmental
agencies as follows: 13
•

“Develop a common vocabulary that laboratories can understand”

•

“Simplified the cumbersome QSR and assist laboratories translate the directives”

•

“Develop a “QSR fit for purpose and harmonize the standard”

Her advice to laboratories was to “invest in a quality management system, implement all factors
of design control, and be proactive and prepare for future regulatory requirements.”13 However,
laboratories lack guidance and direction and the current historical documents refer to medical
device, rather than laboratories. Translation of the requirements to practical laboratory language
is not easy, and the resources required for development of a structure to comply with regulatory
requirements is difficult to estimate.
The Clinical Laboratory Improvement Act has not updated the original laboratory standard since
1988. Four interviewees expressed the need for CMS and the FDA to reach an understanding
regarding requirements and aim towards consistency of purpose prior to a policy release. Shelia
Walcoff of Goldbug Strategies at the 2015 FDA Work shop on Laboratory Developed Tests stated,
“It is essential that FDA harmonize the QSR requirements with CLIA requirements at a more
granular level to prevent duplicate efforts and to ease the regulatory burden, because governmental
agencies have not provided the necessary guidance for struggling laboratories.” 13 The FDA 2017
Discussion Paper addresses this concern by the following statement “Adapting CLIA to enable
CMS to provide the kind of effective oversight of LDTs that is needed to ensure that they are
accurate, reliable, and clinically valid would require a significant change in the nature of what the
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agency does, rather than minor modifications as some have suggested. By its very nature, a CMSonly framework for LDTs could create costly federal redundancies and inefficiencies.” 13 The
oversight of laboratory testing remains with CMS (and CLIA), however, a gap exists regarding the
regulation of test development. Due to the advances in genomic medicine the oversight by CLIA
is no longer adequate to manage the compliance needs of laboratories. This is highlighted by the
significant difference in the oversight between FDA and CLIA. The FDA does not mandate the
operations of testing as stated in 21 CFR 820, while CLIA does not ensure the safety and
effectiveness of test protocols as described in CFR 493. As stated by Interviewee # 1, “there are
no plans for CLIA to update policies at this time.”
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APPENDIX G: SURVEY RESULTS: TOP TEN RESPONSES BY EXPERTS PER
SIGNIFICANCE OF MEANS
1. Leadership: Statement 1: Leadership institutes key performance indicators that outline,
measure and direct regulatory initiatives
2. Leadership: Statement 2: Leadership commitment to initiate and maintain change in the
organization
3. Leadership- Statement 3: The establishment of a QMS includes oversight by a
knowledgeable, educated, responsible, informed, cohesive team to effectively manage the
process
4. Leadership: Statement 5: Leadership consistently communicates change
5. Process Control: Statement 29: Clinical validity is performed to validate whether the
design and optimization of the test protocol will yield testing outcomes that can be used to
develop a useful clinical intervention.
6. Process Validation: Statement 37: A validation plan includes: Process Qualification,
(PQ) Operational Qualification (OQ), and Performance Qualification (PFQ) to verify that
all steps in the process meet or exceed regulatory requirements
7. Process validation: Statement 38: Process Qualification: (PQ) ensures the necessary
components of the process are implemented according to design specifications. Documents
necessary for operation, performance and maintenance are verified and the process
includes all pertinent factors
8. Development of a QMS Framework: Statement 31- The primary step to develop a
regulatory QMS is to define a leadership support structure with defined roles,
responsibilities, and oversight
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9. Training- Statement 7: The course material includes regulatory requirements and terms
and definitions in alignment with CLIA 88, 12 QSEs, 21 CFR 820/QSR and Design Control
10. Document Control -Statement 25: A document control system will ensure documents are
current and are readily available
The MOST important responses by ALL groups per significance of means
1. Leadership: Statement 2: Leadership commitment to initiate and maintain change in the
organization
2. Leadership Statement 5: Leadership consistently communicates change
3. Leadership Statement 1: Leadership institutes key performance indicators that outline,
measure and direct regulatory initiatives
4. Leadership Statement 3: The establishment of a QMS includes oversight by a
knowledgeable, educated, responsible, informed, cohesive team to effectively manage the
process
5. Process Control: Statement 29: Clinical validity is performed to validate whether the
design and optimization of the test protocol will yield testing outcomes that can be used to
develop a useful clinical intervention
6. Pre-Assessment of Existing QMS: Statement 15: A clear understanding of the QSR
requirements is key to implementing processes for a robust regulatory quality management
system
7. Process Validation Statement 37: A validation plan includes: Process Qualification, (PQ)
Operational Qualification (OQ), and Performance Qualification (PFQ) to verify that all
steps in the process meet or exceed regulatory requirements

129
8. Document Control Statement 25: A document control system will ensure documents are
current and are readily available
9. Process Control Statement 28: Documentation of analytical validity will demonstrate and
document the accuracy and reliability of test performance
LEAST important responses by ALL groups per significance of means
1. Development of a QMS Framework: Statement 32: Employee training describes terms,
definitions and regulatory requirements for the development, manufacture and testing of
LDTs
2. Development of a QMS Framework: Statement 34: Review the pre- assessment findings
and create a list of necessary guidance documents in need of development in comparison
to 21 CFR 820 Quality System Regulation will assist laboratory leaders identify and
understand pertinent gaps in the QMS
3. Pre-assessment of Existing Quality Management System
a. Statement 14: A pre- assessment of existing policies, procedures and processes
may reveal informal processes or documents not previously considered compliance
to regulatory requirements
b. Statement 11: The review of existing laboratory processes in comparison to the
list of CLSI 12 QSE management principles will identify policies, procedures or
processes not previously addressed
c. Statement 13: A cross walk of current processes in comparison to 21 CFR 820
Quality System Regulation will assist laboratory leaders identify and understand
pertinent gaps in the QMS
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4. Document Control: Statement 21: Updated and accurate standard operating procedures
serves as verification of compliance
5. Training: Statement 8: The program includes value stream mapping to demonstrate the
significance of hand-offs, tasks and activities and all aspects of the LDT process beginning
with research and development and ending with diagnostic testing
6. Document Control: Statement 23: Record retention and timely retrieval of
documentation related to design manufacture and testing of LDTs demonstrate regulatory
compliance
7. Process Control: Statement 27: The consistent uninterrupted flow of material, product,
and information between hand- off s is critical to demonstrate the user- friendliness of the
framework
8. Leadership: Statement 4: Establishment of an LDT quality committee to quickly
approval changes and provide support
9. Design Control: Statement 20: A procedure that addresses the process for identification,
documentation and reporting of an adverse event is referred to as Medical Device
Reporting
LEAST important statements common to both groups
1. Development of a QMS Framework: Statement 34: Review the pre- assessment findings
and create a list of necessary guidance documents in need of development
2. Process Control: Statement 27: The consistent uninterrupted flow of material, product,
and information between hand- off s is critical to demonstrate the user- friendliness of the
framework
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3. Pre-assessment of Existing QMS: Statement 13: A cross walk of current processes in
comparison to 21 CFR 820 Quality System Regulation will assist laboratory leaders
identify and understand pertinent gaps in the QMS
4. Pre-assessment of Existing QMS: Statement 14: A pre- assessment of existing policies,
procedures and processes may reveal informal processes or documents not previously
considered compliance to regulatory requirement
5. Leadership: Statement 4: Establishment of an LDT quality committee to quickly
approval changes and provide support
6. Document Control: Statement 23: Record retention and timely retrieval of
documentation related to design, manufacture and testing of LDTs demonstrate regulatory
compliance
7. Training: Statement 8: The program includes value stream mapping to demonstrate the
significance of hand-offs, tasks and activities and all aspects of the LDT process beginning
with research and development and ending with diagnostic testing
8. Design Control: Statement 20: A procedure that addresses the process for identification,
documentation and reporting of an adverse event is referred to as Medical Device
Reporting
Strategic Factors - Respondent Feedback
Q9, do you agree with the strategic factors identified in the proposed framework for Quality
Management System of LDTs? If not, please suggest additional factors pertinent to develop a
robust framework
1. Agree, and in fact these are important
2. I think all 12 QSES need to be applied to ANY laboratory project - particularly LDTs.
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3. Aside from the strategic factors outlined I think it would important to get buy-in from
leadership to allow for the time necessary for the implementation of these factors outside
of normal work duties. In addition, each lab using these processes should have at least one
go-to super user that can help navigate these processes.
4. An additional factor is a defined process for management to review and re-evaluate whether
current resources (both personnel and equipment) are sufficient to address QMS gaps,
maintain established processes, and implement changes
Feedback- The Establishment of a Quality Management System Framework
Q10 - Do you think the establishment of a Quality Management System framework will assist
LDT laboratories incorporate regulatory requirements such as design control more readily? If not,
why and what else is necessary?
1. A fully functional QMS is needed for a laboratory to meet accreditation requirements.
Design and document control is paramount in having this happen.
2. The QMS framework will not only assist LDT Lab and also assist clinical lab as well in
compliance with regulatory requirements
3. definitely yes and having a framework that is accepted throughout our industry will set a
level playing 8eld as well provide structure, uniformity and integrity to the entire process
4. Yes, it could help by providing guidance. The biggest issue with some of the most complex
LDT's is the clinical significance, and how results derived from a LDT are being used or
will be used to guide therapy.
5. Yes, the QMS framework will provide these laboratories with the tools to ensure LDT
development is conducted and documented consistently, with demonstration of regulatory
compliance as a by-product.
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6. Yes, a QMS is foundational to building LDTs into a lab.
7. I do think that you could crosswalk each clause of Part 820 to the elements of each QSE
and use the QSEs as the QMS framework for LDTs. QSE Process Management would be
the location of all Part 820 clauses related to design. Everything else in Part 820 comes
from ISO 9001:1994 and sorts easily to each QSE. We used ISO 9011:1994 when we
created the QSEs in 1998.
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APPENDIX H: DESCRIPTIVE STATEMENTS
Descriptive statistics for all 40 statements with corresponding mean and standard deviation.
Descriptive Statistics
N

Minimum Maximum Mean Std. Deviation

Q1_2

33 1

2

1.30

0.467

Q1_5

33 1

2

1.30

0.467

Q1_1

33 1

2

1.33

0.479

Q1_3

33 1

2

1.48

0.508

Q6_4

32 1

3

1.53

0.567

Q3_5

33 1

3

1.64

0.603

Q8_2

33 1

3

1.64

0.603

Q5_5

32 1

3

1.66

0.602

Q6_3

32 1

3

1.66

0.602

Q2_5

33 1

3

1.67

0.595

Q8_1

33 1

3

1.67

0.645

Q4_1

33 1

4

1.67

0.692

Q8_3

33 1

3

1.70

0.585

Q2_2

33 1

3

1.70

0.637

Q7_5

31 1

3

1.71

0.643

Q7_1

32 1

3

1.72

0.581

Q8_5

33 1

3

1.79

0.650

Q2_4

33 1

3

1.82

0.635

Q5_2

33 1

3

1.82

0.808
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Q4_3

33 1

5

1.82

0.846

Q8_4

33 1

4

1.82

0.683

Q3_2

33 1

5

1.88

0.992

Q4_2

33 1

4

1.88

0.781

Q6_1

31 1

3

1.90

0.651

Q5_4

33 1

3

1.91

0.723

Q6_5

32 1

3

1.97

0.782

Q7_3

32 1

4

1.97

0.740

Q2_1

33 1

3

1.97

0.728

Q4_4

33 1

3

1.97

0.684

Q7_2

32 1

3

2.00

0.568

Q5_1

33 1

5

2.00

1.000

Q2_3

33 1

3

2.03

0.728

Q3_1

33 1

3

2.03

0.770

Q7_4

32 1

3

2.03

0.595

Q3_3

33 1

5

2.06

0.827

Q5_3

33 1

3

2.12

0.820

Q3_4

33 1

4

2.15

0.870

Q6_2

32 1

3

2.16

0.628

Q1_4

33 1

5

2.24

0.969

Q4_5

33 1

4

2.39

1.029

Valid N (list wise) 29
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Statement of the Problem: We explore the 2014 draft guidance by the FDA entitled Framework
for Regulatory Oversight of Laboratory Developed Tests (LDT) extended from the medical device
industry and discuss how these requirements may be applicable to laboratory medicine. We
introduce terms, definitions and provide a call for action for leaders to prepare for the potential
adherence to regulatory requirements and explore if compliance was achievable in a laboratory
environment to design, develop and validate Laboratory Developed Tests. If not, why not, and
what would be the limiting steps.
Method: We perform interviews with laboratory professionals to explore their concerns and
challenges regarding the FDA draft guidance then translate the results into strategic factors. Based
on the feedback, we surveyed laboratory experts in the field of LDT to develop and test strategic
factors that would comprise an effective quality management system framework (QMS) to comply
with the FDA proposal. We describe the methodology to translate the strategic factors into a
design that would transform the existing laboratory structure into a regulatory quality management
system.
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Conclusion: Nine interviewees and 35 survey respondents shared the importance of risk
classification, process validation, patient safety and general ambiguity for the development of
LDT. We utilize the top supporting statements and associated factors chosen by experts as
extremely important for LDT development as the building blocks for implementation of a
regulatory QMS framework.

The framework includes six phases of implementation: 1)

establishment of a leadership support structure, 2) training, 3) pre-assessment of current laboratory
processes, 4) adoption of design control, 5) process controls, 6) process validation and the
application of an agile Stage Gate technique for test development.
Respondents agree that a regulatory agile quality management system is needed in laboratories
that develop LDT. Utilizing the strategic factors, we develop a novel approach to LDT design,
development and testing that extends the existing laboratory structure with a proven product
development methodology technique called agile stage gate hybrid with the assignment of
dedicated, accountable cross-functional teams for go/no-go approvals at every step and institute a
coordinator position to review, document and expedite LDT development throughout the testing
process.
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